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ABSTRACT 
The use of aminoglycosides in the treatment of the febrile 
neutropaenic patient with haematological disease is difficult and 
often suboptimal. This study reviews the available literature 
to establish therapeutic guidelines in this population and then 
r eports the use of a Bayesian statistics based predictive model to 
implement and manage therapy in 10 patients. 
A review of the literature on aminoglycoside Pharmacology and 
clinical use is essential to determine therapeutic guidelines for 
this population. Aminoglycosides are amino sugars in glycosidic 
linkage and are polycations at physiological PH. The antibiotic 
effect is mediated through inhibition of protein synthesis and 
disruption of cell membrane integrity. Principal use is in 
treatment of Gram negative infection although aminoglycosides have 
activity against some Gram positive organisms including 
staphylococci. Aminoglycosides are inactive against anaerobes. 
Acquired resistance is mediated by bacterial enzymatic drug 
metabolism. Aminoglycosides are nephro- and ototoxic, this is the 
maJor constraint in clinical use. 
The polar nature of the aminoglycosides results in restriction of 
drug distribution to the extracellular fluid space with clearance by 
glomerular filtration. Although simple and predictable 
pharmacokinetics may be expected, this is not observed in practice. 
Kinetic parameters correlate Poorly with both Physiological 
variables and disease states. There is also evidence that volume of 
distribution (Vd) is increased significantly in seriously ill 
patients and those with neutropaenia. 
The toxic/therapeutic ratio for aminoglycosides is low. Planning of 
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opt imal therapy requires determination of the maximum drug level and 
dosa ge frequency that will not cause toxicity. Thi s demands a 
thorough underst andi ng of the r elati onship between drug kinetics and 
dynamics . Aminoglycoside antibiotic effect in susceptible organisms 
is depends on the drug level ac hi eved in the bacterial cytoplasm. 
Clinical studies have established that the early achievement of high 
Peak level s and high max i mum peak levels are the best predicto rs of 
the r apeutic response. In vitro and animal studies suggest that t he 
peak level :minimal inhibitory cor1centr·ation (MIC) ratio and 
antibiotic killing rates are the best predictors of antibiotic 
effect. The post antibiotic effect CPAE) is we 11 established for 
aminoglycosides and has been investigated extensively as the basis 
for once daily dose therapy, However this is not currently an 
option for neutropaenic patients. 
Aminoglycoside ototoxicity correlates with the area under the 
concentration-time curve CAUC), cumulative dose, duration of therapy 
and trough drug levels. The trough level is the only variable that 
can be monitored and influenced during therapy, 
Nephrotoxicity also correlates with AUC, cumulative dose and 
duration of therapy but the relationship with measured drug levels 
i s· less well established. 
The development of rapid, cheap and reliable assay methods for 
aminoglycosides has allowed the evolution of therapeutic drug 
monitoring CTDM). Early experience with empiric and nomogram based 
methods was disappointing and has resulted in the development of 
computer based individualized predictive models with significantly 
improved performance. The method developed by Sawchuck and Zaske 
CSZ) and the Bayesian statistical based methods are both well 
validated for general hospital patients and intensive care unit 
(ICU) patients. The SZ method has also been used in neutropaenic 
patient with haematological disease but there is no Published report 
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of use of the Bayesian method in thi s population. 
Empiric antibiotic theraPY in febrile neutropaenic patients has 
resulted in a dramatic improval in survival. Gram negative 
orga nisms and staphylococc i comp rise the maJority of documented 
infections in th~s population. Antibiotic protocols usually 
comprise combinations of a Beta- l actam CB-lactam ) and aminoglyc osi de 
although single and double B-lactam regimens are a lso used . A 
review of reports of treatment efficacy and toxicity as well as 
r esistance patterns, suggests that aminoglycos i de containing 
regimens are still optimal therapy in this population. 
The avai l able evidence thus suggests that early achievement of 
therapeutic peak levels (30 +/- 10 mg/1) with avoidance of toxic 
trough levels (>6 mg/1) using multiple daily intravenous CIV) 
inJections results in optimal amikacin therapy, 
Routine therapeutic drug monitoring for aminoglycosides has not yet 
been used at Groote Schuur Hospital. The purpose of this study was 
to validate a Bayesian method in a population at r1igh risk of 
treatment failure and aminoglycoside toxicity in whom use of this 
method has not previously been reported. 
Sequential admissions to the Department of Haematology Isolation 
Unit at Groote Schuur Hospital/University of Cape Town who had 
haematological disorders, required aminoglycoside therapy according 
to Unit treatment protocol criteria and were neutropaenic during 
therapy were enroled. Treatment was initiated by Unit medical staff 
and blood specimens obtained for aminoglycoside level assay by 
nursing staff at 1 hour after the start of administration with one 
further level being obtained in the first dose interval. 
Assays were performed using the flourescent antibody method (Abbott 
TDX). Patient physiological parameters and drug levels were entered 
into the Bayesian model COPT Clydesoft) and initial kinetic 
parameter and dose estimations derived. These were implemented 
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within 24 hours of the onset of therapy, Pea k and trough levels 
were subsequently assayed at least twice a wee k and kineti cs and 
dose estimations re calculated. Therapy was revised according to 
derived recommendat ions. Prediction accuracy was determined by 
compari son of achieved and predicted levels. Bi as was measured by 
calcul ating mean error of prediction CME) and precision by the 
calcul ation of mean absolute error (MAE) and root mean squared error 
CRMSEl. The percentage of achieved therapeutic levels was also 
calcul ated. 
Ten sequential Unit admissions satisfying enrolment criteria were 
studied. Patient age ranged from 15 to 60 years with 6 males and 4 
females. There was one patient death during the study period. Nine 
patients received chemotherapy and the three bone marrow transplant 
patients also received high dose radiotherapy, An initial 1 hour 
peak level was obtained in all Patients but the second initial level 
was obtained in only 9 patients with 1 patients initial estimates 
r equiring use of levels from the second dosage interval. 38 batches 
of assays were performed and the median control value of 14.7 +/-
0.5 mg/1 was within the manufacturers accuracy and variability 
specifications. 
Prediction performance was assessed using 51 paired predicted v~rsus 
achieved data sets. Overall peak level prediction was found to be 
both unbiased and precise while predictions for trough levels were 
biased and precise. Predictions based on f ~st dose level 
measurements were unbiased but imprecise f c oeak levels and biased 
but Precise for trough levels. There was an overall achievement of 
therapeutic peak levels for 80% and therapeutic trough levels for 
94% of levels. 7 patients achieved therapeutic peak levels using 
first dose predictions. In 5 patients a l~ measured levels were in 
the therapeutic range. 
Patient estimated mean kinetic parameters fell within the range of 
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standard deviation of reported values for amikacin and could thus 
not be considered significantly different. 
The use of the OPT Bayesian Program resulted in acceptable but 
suboptimal dosage Predictions in this study. The result was 
inferior to that achieved in other reported studies and especially 
those using initial population kinetics derived from an equivalent 
sample of the same population. The failure to find a significant 
difference in kinetic parameters might have been a result of small 
sample size or inaccuracy of the Bayesian method in calculation of 
exact kinetic parameters or may represent a true result. An attempt 
was thus made to alter the OPT initial population data to improve 
prediction accuracy, This was not successful. The contribution of 
experimental method error influencing the prediction performance is 
unlikely to be significant. A maJor limitation to the performance 
of any predictive model remains the inability to predict inter and 
intrapatient kinetic variability, 
This study concludes that aminoglycosides remain essential 
antibiotics in the therapy of neutropaenic patients with 
haematological disease. Optimal therapy requires multidose daily 
dosing with early and sustained achievement of therapeutic peak and 
non toxic trough levels. A literature review suggests that this goal 
is only attainable with the use of a TOM program such as the OPT 
model. Use .of the OPT model for patients at GSH resulted in the 
achievement of acceptable but suboptimal prediction accuracy. This 
suggests that a Bayesian TOM system can be used in this population 
although improvement of accuracy is desirable. Model performance can 
be improved with increased experience and use of more appropriate 
initial kinetic parameters. However the basic constraints imposed 
by aminoglycoside kinetic variability will continue to limit 
performance accuracy until a better understanding of the mechanism 
and correlates of this variability is developed. 
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.1...... INTRODUCTION 
Aminoglycosides are valuable antibiotics with a well established 
role in clinical medicine. 
Therapeutic use is limited by the need to maximize the concentration 
dependent antibiotic efficacy of a drug with a low therapeutic:toxic 
ratio. Accurate drug use is thus essential for effective and safe 
treatment. Achievement of this goal is complicated by the lack of 
sufficient data to establish reliable target drug level and dosage 
frequency guidelines. This is a result of the difficulty in 
performing controlled trials of effectiveness in seriously ill 
patients in whom physiological and disease variables cannot be 
adequately controlled. The complexity of therapy is compounded by 
the large inter- and intrapatient Pharmacokinetic variability for 
aminoglycosides especially in the seriously ill. Treatment of 
neutropaenic patients requires further consideration due to reports 
of altered kinetics and especially volume of distribution (Vd) in 
this population. 
This study will review the Pharmacology of aminoglycosides so as to 
explain the basis of current treatment regimens. Clinical medicine 
requires therapeutic guidelines for the use of aminoglycosides in 
neutropaenic patients with haematological disease despite the 
uncertain and incomplete nature of available data. Provisional 
treatment recommendations are thus proposed. 
The need for therapeutic drug monitoring CTDM) for accurate 
implementation of aminoglycoside treatment in the seriously ill 
patient is well established. This evidence is reviewed. The novel 
experimental use of a Bayesian TOM pharmacokinetic model for 
amikacin therapy in neutropaenic patients with haematological 
disease in a study performed in the Department of Haematology Source 
Isolation Unit at Groote Schuur Hos~ital is then reported. 
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l.....l AMINOGLYCOSIDE CHEMISTRY 
The aminoglycoside antibiotics are amino sugars in glycosidic 
linkage (aminoglycosidic aminocyclitols). The aminoglycosides 
commonly used in South Africa for systemic therapy ( gentamicin, 
tobramycin, amikacin and netilmicin) have similar chemical and 
Pharmacological characteristics. 
The agent used in this study is amikacin which was first synthesized 
in 1972. It is a semisynthetic antibiotic derived from kanamycin by 
acylation of the 1 amino group of the 2 deoxystreptamine moiety with 
2 hydroxy 4 amino butyric acid (1) . 
.L.2 PHARMACODYNAMICS 
1 .2.1 .D.filJ.G ACTION 
The aminoglycosides are rapidly bactericidal in adequate 
concentration for susceptible organisms. The mechanism of action is 
not fully understood and is believed to involve several steps. 
Research has been conducted mainly on Gram negative organisms. 
Aminoglycosides enter the periPlasmic space through aqueous channels 
formed by porin Protein (1). Transport across the inner or 
cytoplasmic membrane is an energy dependant active process which is 
inhibited by divalent cations eg Ca++ and Mg++ (2), increased 
osmolalitY, decreased PH and an anaerobic milieu (1) (3). During 
this Phase the drug probably causes disruption of the cytoplasmic 
membrane, initially causing leakage of small ions and later larger 
molecules. This is believed to be a major component of antibiotic 
action C 1 ) . 
Within the bacterial cytoplasm, aminoglycosides bind to ribosomal 
components with greater affinity for 30S than 50S subunits C1). 
This results in both the inhibition of protein synthesis and the 
8 
accumulation of abnormal initiation complexes. There is loss of 
transl at ion fidelity with misreading of the mRNA code (1). 
A combination of disruption of the integrity of the inner or 
cytoplasmic membrane integrity and inhibition and loss of fidelity 
of protein synthesis may explain the rapidly lethal effect of the 
drug . 
1 .2.2. QfillG. RESISTANCE 
Clinically relevant resistance to the action of aminoglycosides may 
be due to chemical drug inactivation, impaired penetration of the 
bacterial cell membrane or enzymatic degradation in the periplasmic 
space. 
Chemical inactivation occurs in areas of low PH eg pus, and high 
divalent cation concentration and osmolality eg the renal medulla. 
Failure of permeation of the cytoplasmic membrane occurs in 
anaerobic organisms which have a poorly developed active transport 
mechanism (1). 
The principal mechanism of acquired resistance is the enzymatic 
inactivation of the drug in the periPlasmic space. Frequency of 
such resistance is largely determined by the extent and duration of 
antibiotic use (4). Aminoglycosides are inactivated by 
adenylation, Phosphorylation and/or acetylation of specific hydroxyl 
or amino groups (1) (4) by enzymes coded by Plasmids and resistance 
transfer factors (1). Several resistance enzymes may coexist in 
the same organism and sequential enzyme action is important as a 
mechanism for amikacin resistance (4). 
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1......3. PHARMACOKINETICS 
The kineti cs of aminoglycosides are determined by their chemical 
cha racteristics. Aminoglycosides are Polycations at phys iolog ic al 
PH and therefore cannot easily cross biological membranes and have 
limi ted access to body fluid spaces. 
1 .3.1 ADMINISTRATION 
Am i noglycoside absorption from the gastrointestinal tract is< 1% 
( 1 ) . Parenteral admi ni strati on is thus essential for system use. 
Int ravenous injection is a reliable method and is generally employed 
i n ill patients with unpredictable tissue perfusion. Intramuscular 
i nJection yields peak levels equivalent to those obtained with 
in travenous infusion. However absorption from muscle is unrel i able 
in the elderly and seriously ill. 
The most popular method of administration is Pulsed continuous 
i ntravenous infusion which is believed to be safe and effective 
(3) . Bolus injection may result in increased ototoxic i ty (3), and 
continuous infusion is of no Proven therapeutic value and has 
i ncreased toxic potential (3). 
1 ,3.2. DISTRIBUTION 
Aminog l yosides are charged at physiological PH and distribution is 
r estricted to the extra cellular space. Penetration of 
extravascular fluid spaces is variable. There is good penetration 
of cochlear and vestibular perilYmPh and endolymph (1) and 
concentrations 5 -10 x those of serum are achieved in the renal 
t issue fluid (1) (5). Entry of drug into the Pleura, ascitic and 
synovial fluid is slow but high levels are obtained with continued 
use (1) (3). Penetration of bronchial secretions is variable (1). 
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There iS active hepatic secretion into bile with l evel s of 
approxi mately 30% of that of serum being achieved (1) . Penetrat ion 
of prost at i c and amniotic fluid is slow and incomplete (3). Ther e 
i s poor penetration of the blood brain barrier. Cerebrospinal 
spinal fluid levels reach only 20% of the serum level i n the 
presence of meningeal inflammation Cl). Aminoglyosides do not enter 
the eye (1). The drug is excluded from all cells with the except ion 
of those of the proximal renal tubules where uptake is by Pinoctosis 
(6). Aminoglyoside plasma Protein binding is less than 10% and has 
no kinetic significance C 1 ) . 
1 ,3,3, ELIMINATION 
90% of excretion is by renal glomerular filtration with a small 
amount of drug being excreted in the bile (3). A small but variable 
degree of renal tubular reabsorption occurs. Aminoglycoside 
clearance (Cl) is approximately 65% that of creatinine clearance 
Cl) (7) but correlation is variable as creatinine is excreted by 
glomerular filtration and tubular secretion (7) (8). A wide 
variation of drug clearance occurs in both health and disease (3). 
1 ,3,4, KINETIC MODELS 
Aminoglyosides are restricted to the extracellular fluid, have 
minimal plasma Protein binding and are cleared primarily by 
glomerular filtration . Kinetics should thus be expected to be 
simple. However this is not observed in practise and there is no 
reliable and accurate kinetic model explaining observed experimental 
concentration - time curves. 
Aminoglyosides have at least triexponential kinetics (9) and the 
optimal model for accurate fit comprises three compartments. The 
first component represents the rapid distribution Phase during drug 
administration and has a half life (tl/2) of less than one hour. 
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The second compartment is the central compartment of distribution 
and has a volume of distribution CVd) of 0.11 to 0.31 1/kg body 
weight and a t1/2 of approximately two hours which corresponds 
closely to the elimination t1/2 reported in the one compartment 
model analysis. The third compartment represents deep tissue 
accumulation of the drug. This occurs Principally in renal tissue, 
which has the highest tissue to serum concentration ratio, and 
skeletal muscle which has the greatest storage capacity. The Vd of 
this compartment is 0.45 to 1 .34 1/kg with a t1/2 ranging from 40 
hours to several days (3) (10). 
Use of the three compartment model requires multiple samples to 
establish an accurate concentration time curve and the use of a 
complex mathematical model to determine kinetic Parameters. 
A simplified one compartment model has been shown to be 
sufficiently accurate for clinically valuable estimation of 
aminoglycoside kinetic parameters (3). Use of this model requires 
IV drug administration .with sampling delayed until the completion of 
the initial distribution Phase thus allowing the first compartment 
to be ignored for subsequent mode 11 i ng purposes C 11) < 1 2) . There is 
no simple method of compensating for the inaccuracy caused by the 
third or deep tissue compartment. Gradual accumulation in the slow 
exchange deep muscle and renal compartment results in some 
inaccuracy when using the one compartment model which fails to 
predict the slow rise in peak ·and trough levels with prolonged use 
of the drug especially in excess of 10 days (10) (13). 
1 ,3,5, VARIATION IN. KINETIC PARAMETERS 
Aminoglyoside kinetic parameters demonstrate considerable inter- and 
intra individual variability due to both physiological and 
pathological factors. This variability remains poorly defined and 
-
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explained. However a discussion of the available data is 
essential to facilitate an understanding of the intrinsic 
limitations of kinetic predictions in therapeutics . 
The initial kinetic research on aminoglyoside was performed on 
healthy subJects and usually involved studies of single dose 
administration . Subsequent kinetic studies in clinical Practise 
have revealed significantly different parameters with the most 
prominent feature being wide variations in Vd , Cl and t 1/2 . 
i2.. PhYsioJogicaJ Factors 
a) Age: Paediatric Vd is significantly greater and tl/2 
significantly lower than adults, but no correlation exists between 
Vd and age if corrected for creatinine clearance. (3) ( 14) . 
b) Body Weight: Extra cellular fluid CECF) volume usually 
correlates with body weight . The Vd of aminoglycosides has been 
estimated at 19% of ideal body weight Plus 6% of weight in excess of 
i deal body weight (3). However some studies have shown body weight, 
both actual and ideal , to correlate poorly with measured Vd , a 
study performed on patients in a Surgical Intensive Care Unit (ICU) 
Yi elded a r value of 0 . 32 for the relationship between Vd and body 
weight (12) . Most patients have a Vd for aminoglycosides in exces s 
of the value for the volume of extra cellular fluid calculated from 
body weight (12) . 
c) Sex : Females tend to have a lower Vd because of decreased muscle 
mass and a decreased ECF : weight ratio . Pregnancy causes 
bott1 an increase in Vd as the ECF compartment increases and an 
increase in Cl with increased cardiac output and GFR (3) . 
d) Renal Function: There is no reliable clinically available 
indicator of the renal clearance rate of aminoglycosides . A wide . 
variation in elimination occurs amongst patients with normal 
creatinine levels and creatinine clearance rates . In healthy 
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volunteers the tl/2 for amikacin ranges from 0.8 to 2.8 hours and 
for gentamicin from 2.5 to 4 hours (3). The relationship between 
gentamicin clearance and calculated creatinine clearance is r = 0.42 
(7) and r = 0.55 for correlation with measured creatinine clearance 
(15). The r value for correlation between tl/2 and serum creatinine 
has been reported as 0.35 (11). The variability in drug elimination 
rate as predicted by changes in serum creatinine has been reported 
as 50% for Surgical ICU patients (12) and as between 40% and 50% in 
other studies (3) (16). Thus although renal function is the most 
important predictor of clearance. the correlation between creatinine 
clearance and aminoglycoside is relatively poor. 
e) Temperature: Experimental work in dogs using endotoxin has 
demonstrated an increase in Cl during pyrexial illnesses secondary 
to an increase in GFR (3). 
Age. weight. sex. renal function and temperature are physiological 
variables affecting kinetic parameters. However. correlation is 
relatively poor and resultant kinetic parameters predictions 
unreliable. 
iil. Effects Qf Disease 
Aminoglyosides kinetics show increased inter- and intrapatient 
variability in disease states. This can only be partially 
explained by the alterations in fluid status and renal function 
which are especially prevalent in patients with septicaemia. 
a) Infection: Significant increases in Vd occur except when 
patients are severely dehydrated <15) C17). A wide range in 
parameters occurs in gram negative pneumonia with a Vd mean of 0.21 
l/kg with a range of 0.10 - 0.46 l/kg and a t1/2 of 0.7 - 6.6 
hours being reported in patients with normal serum creatinine levels 
(18). Intrapatient variations in Vd over 24 hours range from 
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decreases of 42% to increases of 91% with a mean absolute
 change of 
20% (1 1). IntraPatient changes in clearance range from a
 reduction 
of 39% to an increase of 36% with a mean absolute change 
of 17% 
(11). A large study of critically ill surgical Patients
 (19) 
revealed maJor intrapatient variations during the course 
of therapy, 
The Vd changed by more than 1 litre in 83% of patients an
d by more 
than 5 litres in 48% of patients with a change in clearan
ce of 
greater than 10 ml/min in 51% of patients with the highes
t value 
being 108 ml/min. Poor and inconsistent correlation betw
een changes 
in body weight and Vd and changes in creatinine clearance
 and 
aminoglycoside clearance was found. There is no adequate
 
explanation for these findings although some authors prop
ose that 
septic patients may initially have large volumes of distr
ibution 
which decrease as the patients clinical condition improve
s (11). 
The increased measured Vd may also be due to failure to c
onsider 
exogenous volumes administered as well as increased micro
vascular 
permeability with loss of fluid into the interstitial spa
ce 
resulting in ECF accumulation (12). 
b) ECF volume alteration: Ascites. congestive cardiac fa
ilure and 
the Presence of Pleural effusions increase Vd (3) (15). 
c) Burns: Significant increases in both Cl and Vd occur (
3)(20). 
d) Cystic fibrosis: 
( 3) . 
Increased drug clearance has been documented 
e) The neutropaenic patient: Several studies have suggest
ed 
significant differences in aminoglycoside kinetics in neu
tropaenic 
patients. However this issue remains controversial. 
In a prospective uncontrolled study on 35 patients (21) 
aminoglycoside Vd and Cl were found to be significantly i
ncreased in 
patients with solid and haematological malignancy treate
d with 
empiric antibiotics. There was no correlation between ki
netic 
changes and sex. type of malignancy, age or serum albumin
. 
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Clearance was increased 63% (P< 0.05) and Vd increased 14% 
(P < 0 .05) as compared to population kinetic Parameters used. Due 
to the use of a historical control and the known variability in 
population parameters , the value of this study in establishing a 
relationship between changes in kinetic parameters and white bl ood 
cell counts is small. 
Bianco et al report a prospective control comparison of gentamic in 
ki netics in 34 febrile neutropaenic patients as compared to 40 non 
neutropaenic patients matched for age, sex , weight and renal 
function (7). The study was predicted to have a 95% chance of 
predicting a 22.5% difference in Vd. No difference in kinetic 
parameters was found but both groups had a volume of distribution 
mean of 0.31 1/kg actual body weight CABW) which is higher than the 
0.25% 1/kg AWB used as a control in the previous study. 
AndreJak and Hary compared kinetics in eight non febrile severely 
neutropaenic patients (count less than a 500/mm~3) with eight 
healthy volunteers using amikacin and a two compartment model with 
nine post infusion measurements (22). They conclude that both Cl 
and Vd are significantly increased in the neutropenic patients. The 
mean+/- SD value for Vd was 0.45 +/- 0.05 1/kg ABW and the 
clearance mean+/- SD was 2.55 +/- 0.19 ml/min/kg, Despite the 
small numbers, the study used accurate kinetic methods and excluded 
the effect of pyrexia. The authors propose that neutropenia is 
associated with vascular endothelial damage which causes 
interstitial oedema thus increasing both the extra cellular fluid 
volume and the volume of the distribution of aminoglycosides. 
Zeitany et al conducted a prospective study on aminoglycoside 
parameters in 27 patients with haematological malignancy, fever and 
neutropaenia C23) . A matched control group of eighteen patients 
was used. The authors conclude that Vd is consistently and 
significantly increased in haematological malignancy with a mean+/-
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standard deviation CSD) value of 0.40 +/-0.10 1/kg compared to 0.27 
+/- 0.05 1/kg for the control group c p < 0.004). No difference 
between diagnostic groups was noted. Clearance was significantly 
increased at a mean+/- SD value of 116.7 +/- 48.9 ml/min compared 
to 68.6 +/-26.7 ml/min for the control group CP< 0.005). Patients 
in this study required larger amounts of drug to achieve therapeutic 
levels with a mean increase in requirement exceeding the 
manufacturers recommendations by 100%. No significant difference 
was reported for kinetic parameters for patients before and after 
treatment with chemotherapy, 
Manny and Hutson report a retrospective study in 32 haematology and 
oncology patients with no clinically evident extracellular fluid 
accumulations (24). The authors did not comment on neutroPhil 
counts or treatment status with respect to the administration of 
chemotherapy, The Vd was reported as mean +/-SD of 0.41 +/-0. 13 
1/kg, 
Phillips et al C25) reported on Vd for gentamicin in 24 Patients 
wit h haematological disease and neutropaenic fever. An increased Vd 
was found in the study population compared to a literature derived 
value for the "general population" i.e. mean +/-SD of 0.425 +/-
0.041 1/kg compared to 0.249 +/- 0.006 1/kg CP<0.001). No patients 
had Pleural or peritoneal effusions. No significant correlation was 
found between Vd and age, sex, serum albumin level, haematocrit, 
Platelet count, neutroPhil couQ~ or disease type or activity, 
Chemotherapy in the preceding 21 days was associated with an 
increased Vd. 
The currently available data suggests that Vd is increased for 
aminoglycosides in the neutropaenic patient. However no prospective 
controlled study of kinetics in this population has been reported 
and the issue remains controversial. There is also no tenable 
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mechanism to suPPOrt a claim for altered kinetics. The si gnificance 
of neutropaeni a in the therapeutic use of aminoglycosides and 
its role in the use of TOM remain to be established . 
.l....il: Iha KINETIC= DYNAMIC RELATIONSHIP 
Determining the relationship between aminoglycoside kinetic 
parameters and therapeutic effects, facilitates safe and effective 
drug use. This section discusses the relationship between the 
concentration - time curve and aminoglycoside antibiotic and toxic 
effects so as to propose a rational basis for therapeutic use. 
1 ,4.1, I.HE. ANTIBIOTIC EFFECT QE AMINOGLYCOSIDES 
Maximal antibiotic effect occurs when high tissue are achieved and 
maintained. This may however occurs at the expense of unacceptable 
toxicity. Thus an optimal treatment regimen based on reliable data 
on effective drug levels and using the lowest dose for the shortest 
Period possible should be determined. 
Current knowledge is based on in vitro and animal experiments and an 
incomplete reported clinical experience . 
.il. .D..c.u.g Administration 
Use of the intravenous (IV) route is essential for reliable delivery 
to seriously ill patients with intramuscular (IM) administration 
being reserved for less serious infection in younger patients with 
well preserved muscle mass. 
Continuous IV infusion has been used (26). This is probably less 
effective and more toxic and expensive than intermittent dosing 
(27). Interval therapy can be either by intermittent infusion or 
bolus dose. The bolus dose method is cheaper and easier but 
believed by several authorities to have increased toxic potential 
with out therapeutic advantage (3) C 28) . Intermittent infusion at a 
constant rate over a period ranging from 15 to 60 minutes is 
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cu rrent ly the most popular method. This decreases the height of the 
Peak level during the initial distribution phase and t ogether with a 
delay in initial sampling facilitates use of a single compartment 
kinetic model for prediction. 
This study uses a constant 30 minute infusion with peak l evel 
sampling at 1 hour after the start of the infusion. 
iil. setting Jar9et Kinetic Parameters 
Optimal peak and trough target levels and dosing frequency are not 
known. The following discussion reviews the kinetic -dynamic and 
microbiological data relevant to establishing acceptable therapeutic 
guidelines. 
Aminoglycoside bactericidal effect is Principally dose dependent 
(29). Efficacy depends on the antibiotic levels achieved within the 
bacterium. Drug entry occurs down a concentration gradient although 
a refractory period has been demonstrated after about 6 hours of 
continuous exposure (30). There is no evidence that saturation of 
antibiotic effect occurs with increasing concentration (31). The 
time of exposure to high levels of drug may be of lesser importance 
with variable correlation with bacteriocidal effect among different 
organisms. Pseudomonas and Serratia species appear to require 
longer periods of drug exposure to ensure organism death (32). Kill 
ra tes have been shown to correlate with the area under the 
concentration - time curve (29). Further considerations in 
Planning treatment are the therapeutic value of the post antibiotic 
effect, the importance of rapid achievement of therapeutic levels 
after commencement of therapy and the risk of bacterial regrowth 
during Prolonged periods of suboptimal antibiotic levels. 
a) Clinical Studies: Several studies attempting to identify kinetic 
Parameters determining drug efficacy are discussed. It is important 
to note these studies are uncontrolled. it is considered unethical 
to fail to treat Gram negative infec~ion. However historical 
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controls from the Pre-antibiotic era can be used for approximate 
comparison . Prior to the use of antibiotics documented Gram 
negative bacterial infection was frequently but not universally 
fatal with a surv ival of up to 68% being reported (10 ) . 
In a metaanalysis of 4 randomised double-blind studies comparing the 
use of various aminoglycoside containing regimens in Gram nega ti ve 
infections (33) Moore et al found that factors relating to one hour 
peak drug levels were significant in Predicting the therapeutic 
res ponse. Early achievement ie. within 24 to 48 hours, of 
therapeutic peak levels C> 20 mg/1 for amikacin) was a significant 
factor improving therapeutic response and survival. 
The individual report of one of the studies analysed by Moore et al 
in (33) correlates peak aminoglycoside levels with therapeutic 
outcome in 37 patients with Gram-negative pneumonia (34). Peak 
leve l s C> 24 mg/1 for amikacin) were associated with improved 
survival. This was shown to be a more significant factor than 
initi al temperature, polymorph count or age. The achievement of a 
maximum peak level during therapy of > 28 mg/1 was an independent 
si gnificant correlate for survival. 
A further study by Moore et al (35) reported the correlation of 
maximum and mean peak concentration/ minimal inhibitory 
concentration CMIC) with clinical response. A maximum peak level / 
MIC of > 4 correlated with a response rate of 70% which increased to 
80-90% if the ratio was greater than 1 :8 (36). There was no 
correlation between trough level or geometric mean of the serum 
concentration and clinical outcome. This finding is supported by 
the results of other studies (23) (33) . 
. b) Clinico - Microbiological Studies: Attempts have been made to 
define therapeutic levels on the basis of in vitro bacterial studies 
and measurement of the correlation between drug levels, serum 
bacteriocidal characteristics and clinical response. This approach 
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provides valuab le clinical data but does suffer from several 
distinct limitations: 
1) Tissue fluid aminoglycoside levels correlate with serum levels 
(5) . However the relationship between drug dose and serum levels is 
inconsist ent with drug levels changing constantly during the dosage 
interval. Tissue accumulation of aminoglycosides also occurs with 
ongoing use. Thus neither knowledge of the size of drug dose used 
nor of serum drug levels achieved reliably predict tissue drug 
l evels. The clinical value of the observed in vitro response to a 
constant drug level is thus limited. 
2) Interpretation of the significance of in vitro antibiotic 
effectiveness testing is difficult. Early antibiotic research using 
penicillin in the 1940's established the importance of the serum 
coneentration :MIC ratio in measuring antibiotic effects (10). Due 
to the antibiotic characteristics of beta lactams CB-lactams), the 
Principal of requiring the maintenance of drug levels above the MIC 
for that agent for most of the drug interval was established. This 
i s however neither necessarily true or optimal for aminoglycosides 
which have fundamentally different antibiotic effects and kinetic 
-dynamic relationships. Furthermore testing of the MIC has 
significant limitations. While MIC is valuable for determining 
bacterial resistance to an antibiotic it is of less ·use in 
quantitating bacterial susceptibility to a drug C32). This is 
Primarily due to the larger in vivo bacterial load (10) and the 
inability of the MIC to take into account the dynamic nature of the 
inter dose drug level. The antibiotic killing rate has thus been 
proposed as a more accurate measure of antibiotic effectiveness 
(32). This measures the time kill and regrowth patterns of cultures 
exposed to Patient serum. 
3) Uncertainty as to the microbiological mechanism and clinical 
significance of the post antibiotic effect <PAE>. The PAE is the 
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observed in vit ro Phenomenon of persistent suppression of bacter ial 
growth after cessati on of exposure to antibiotic. It is defined as 
the difference in time taken for previously drug exposed cultures to 
increase ten f ol d above the count Prior to drug removal as compared 
to untreated cultures (29). The duration of aminoglycoside PAE 
increases with higher drug concentrations and after longer periods 
of exposure C 27) C 29) . 
Current data suggests that aminoglycoside antimicrobial activity can 
best be described by a combining data for MIC and minimal 
bacteriocidal concentration CMBC), the rate of bacterial killing, 
and the sub MIC and post antibiotic effects. The antibiotic killing 
rate and PAE data for aminoglycosides will be discussed in further 
detai 1. 
The antibiotic killing rate is a dynamic measure of antibiotic 
efficacy that is performed on serum levels taken at timed interva l s 
after a dose. A study using serum collected from healthy 
vol unteers after a single dose of amikacin has been reported (32). 
Serum killing rates were determined for standard strains of E. coli, 
Enterobacter c 1 oacae, Serrat i a marcescens and Pseudom·onas aerogi nosa 
using samples taken after a 30 minute infusion of either 7.5 mg/kg 
or 15 mg/kg amikacin IV. A one hour peak level of 20 - 30 mg/1 was 
achieved at the lower dose which had substantial but submaximal 
bacteriocidal activity against E. coli and Enterobacter cloacae 
while the 15mg/kg dose achieved a one hour peak level ranging from 
45 - 77 mg/1 which was fully bacteriocidal for these organisms. The 
minimum concentration of regrowth CMCR) for these organisms was 
r eached at 3 hours for the 7.5 mg/kg and 6 hours for the 15 mg/kg 
doses. The results for Pseudomonas aeroginosa and Serratia 
marcescens show relatively decreased bacteriocidal activity allowing 
determination of an index of surviving bacteria. This was 
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significantl y less for the larger dose at 3 hours but the percentage 
for both doses ranges from 50 - 75%. 
The PAE for aminoglycosides is only s i gnifi cant if organisms are 
exposed to levels exceeding 2 x MIC for periods of at least 2 hours 
(27) with maximal effect reported at 5 - 10 x MIC for a minimum 
exposure period of 2 hours < 16) <31) . The mechanism of PAE is 
unknown. Proposed mechanisms are Persistence of the drug at the 
site of action and drug induced non lethal damage <27). A wide 
range of PAE durations have been reported. Aminoglycoside PAE 
against various organisms has been reported as 0.5 - 1 .5 hr for 
Staphlococcus aureus, 0.5 -2.5 hr against Enterobacteriacae and 1 .5 
- 2.5 hr against Pseudomonas aeroginosa (29). Other publications 
quote a non specific period of 2 - 6 hr (27)(31). 
c) The Neutropaenic Patient: This group of immunocompromised 
patients require an increased serum bacteriocidal titre for 
equivalent antibiotic therapeutic responses. In one study (36) a 
bactericidal titre of > 1 :16 resulted in an equivalent clinical 
response to that achieved with a titre of 1 :8 for Gram negative 
septicaemia in non neutropaenic patients. Animal experiments 
measuring PAE have shown equivalent duration of effect in 
neutropaenic patients (27) (29). However there is some evidence of 
bacterial regrowth with potential for treatment failure if serum 
levels are below MIC for prolonged periods of the dosage interval 
( 3) . 
iiil Treatment Recommendations. 
Interval therapy with 2 - 4 equal IV infusions of amikacin per day 
has been standard therapy, Recent work has however suggested that 
once daily therapy using an equivalent total dose may be equal or 
even more efficacious with decreased toxicity and expense. Dosage 
recommendations and therapeutic target levels have also been 
increased especially for compromised patients with serious 
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inf ect ion . 
a) The Once DailY Dose: The theoretical basis for daily use of 
aminoglycosides is based on the role of the PAE, increased 
bact er icidal activity after higher doses and the effect of tissue 
drug accumulation. Due to aminoglycoside concentration in renal 
tissue, there is a large experience of successful treatment of 
urinary tract infection in humans using single daily doses of 
aminoglycosides (5) (37). Treatment of Gram negative infection in 
animals has shown that equal (2) or improved results (10) can be 
achieved with single or multiple dose administration as compared to 
continuous infusion of the same total daily dose. 
A study using netilmicin to treat Gram negative bacteraemia 
randomised 70 patients with normal renal function to either single 
or multiple dose therapy using 6 mg/kg/day (30). Equal efficacy and 
safety was reported. Single daily dose therapy has also been used 
effectively for treatment of Gram negative pneumonia in cystic 
fibrosis (3). This is supporting evidence for the proposed 
theoretical advantage of enhanced penetration of broncho-pulmonary 
secretions at the high peak levels achieved. 
There is concern that prolonged periods of sub MIC serum drug levels 
may cause break through bacteraemia especially if peak level: MIC< 
1 :8 (15) (16) (38). This issue is controversial (23) and acquires 
Particularly importance in considering use of single dose daily 
therapy in seriously ill patients especially those with neutropaenia 
infected with Pseudomonas or Ser rat i a species (31) (39) . While 
single daily dose therapy has been shown to be effective in the 
neutropaeniC mouse thigh model (31), extrapolation to human disease 
i s not necessarily valid. No human clinical trials have been 
reported. 
A multiple dose form of aminoglycoside therapy as used in this study 
thus has a rational basis according to available data. 
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b) Target Therapeu t ic Levels: A proven strategy for targeting 
therapeutic levels remains elusive. Efficacy depends principally on 
pea k levels . Trough levels are of little demonstrated significance 
and are not reliable indirect indicators of the Proporti on of the 
dosing interva l that the drug level is below the MIC. The effective 
serum bacteric i dal titre for aminoglycosides is significantly higher 
in neutropaenic patients and thus higher peak levels are required 
for equivalent therapeutic effect. 
The target therapeutic pea k level in this study was 30 +/- 10 mg/1 
which is believed on the basis of the literature reviewed, to 
represent effective th~raPY in the study population. There is 
however no definite empiric basis for believing that th i s represents 
the optimal therapeutic target. Rapid achievement of target levels 
was also a therapeutic goal. 
J .4.2. AMINOGLYCOSIDE TOXICITY 
The Pr i ncipal limitation of aminoglycoside therapy is toxicity. 
Ototoxicity and nephrotoxicity cause significant morbidity and 
nephrotoxicity can contribute to mortality in seriously ill 
patients. 
The kinetic - toxic relationship for aminoglycosides is poorly 
defined and remains controversial. This is Partly explained by both 
interpatient variability in kinetics and susceptibility to toxic 
effects as well as the inability to accurately predict drug 
accumulation in target organ tissue. Ototoxicity research is also 
hindered by the absence of a good animal model of cochlear and 
vestibular damage. Clinical studies are limited by the difficulty 
of obtaining cooperation from seriously ill patients and the problem 
of background noise in the typical ICU environment. 
Data on the correlation between serum drug levels, duration of 
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theraPY, concomitant pathological and Physiologica l fact ors and drug 
t oxi city is reviewed in this section. 
il OtotoxicitY 
a) Mechanism: High concentrations of aminoglycosides i n PerilYmPh 
and endolymph cause potentially irreversible damage to cochlear and 
vestibular hair cells. The drug diffuses readily into Peri and 
endolymph but elimination is relatively slow, allowing drug 
accumulation to a degree proportional to the area under the serum 
concentration - time curve (AUC) (3) (6). 
The exact mechanism of hair cell damage is uncertain. 
Aminoglycosides inhibit the hair cell membrane Na+ - K+ ATPase which 
alters membrane potential (6). Binding to eel l membrane 
Phosphoinositol specific PhospholiPase C causes inhibition of 
prostaglandin production and the resultant decreased levels of 
cytoprotective prostaglandins may facilitate endotoxin mediated 
cytotoxicity (6) (40). 
b) Clinical Features: The outer hair cells mediating high frequency 
C > 4000 Hz) sound reception are affected first (3). This is 
usually asymptomatic but may result in tinnitus or a feeling of 
fullness in the ears. The deficit is readily detected by tone 
audiometry and usually reverses on cessation of aminoglycoside use 
( 4 1 ) . 
Subsequent destruction of hair cells mediating low frequency hearing 
results in a clinically detectable deficit which is usually 
bilateral. symmetrical and irreversible (3). Hearing deficits 
usually become apparent during therapy but have been documented to 
occur up to 6 weeks after the cessation of drug use (3). 
Vestibular damage tends to parallel cochlear damage, Clinical 
features include vertigo, dizziness. nausea and nystagrnus. Damage 
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is usua l ly reve r sible and compensation occurs through the use of 
vis ua l mechanisms. Profound deficits occur with increased freque ncy 
in t he elde r ly (3). 
c) Inc i dence: A wide range of incidence of toxicity is reported. 
Th is reflects variability in both the definition and measurement of 
ototoxicity as well as differing susceptibility between groups 
studied. 
The reported incidence of clinically evident ototoxicity incidence 
ranges from < 1% (15) to 0.5 - 5% (6) and 2 - 10% (3). 
Audiometrically diagnosed ototoxicity defined either as an increase 
in hearing threshold of> 15 or> 20 dB occurs with an incidence 
ranging from 22% (40) to 43% (3). 
d) Risk Factors: 1) Drug related: Ototoxicity correlates well with 
the accumulation of drug in the deep tissue compartment. This is 
well represented by the area under the serum concentration -time 
curve (10), the cumulative total dose (16) (28) (40) and the 
duration of therapy (10) (13) (16) (28) (40). Increased amikacin 
ototoxicity occurs when the cumulative dose exceeds 15 g or 
treatment continues for > 1 O days (41 ) . 
Total dose and treatment duration guidelines are of limited value in 
treating seriously ill patients requiring aminoglycoside therapy, 
Manipulation of individual doses to achieve non toxic drug levels is 
however possible. 
A significant correlation between elevated trough levels and 
ototoxicity exists (3) (16) (40) C41) (42) and one study (13) using 
multivariate analysis identified an elevated trough level as the 
single most important determinant of ototoxicitY. 
The evidence for a significant correlation of peak level with 
ototoxicity is less convincing, An increased risk of ototoxicity 
correlating with a peak amikacin level > 32 mg/l has been reported 
(3) (41) (42). This finding is not substantiated by other studies 
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wi th no increase in toxicity being reported for pea k l eve l s 
maintained in the range 20 - 40 mg/1 (40 ) and multivariate analys i s 
f a ili ng to es tablish peak levels as a independent risk factor for 
otot oxi citY (13). Massive single aminoglycoside overdose does not 
cause ototox i city C 1 0) . 
There is limited evidence that continuous infusion is more ototoxic 
(43) . 
The ototoxicity risk for amikacin tobramycin and gentamicin is 
believed to be equivalent with unsubstantiated evidence for 
decreased toxicity risk for neti lmicin (3). 
2) Non Drug Related: Age has been shown in one study to be a 
s i gnificant risk factor on multivariate analysis (16). This is not 
however supported by the findings of other studies (41) (42). 
The presence of bacteraemia and high peak temperature correlates 
significantly with ototoxicity on multivariate analysis 
(16) (28) (40). 
The role of renal function impairment as a risk factor for 
ototoxicitY is controversial. Although there are reports of 
significant correlation between the degree of functional impairment 
and the risk of ototoxicitY (28), no correlation was found when 
therapeutic drug levels were maintained (40) (41). 
Hepatic failure is a significant risk factor for ototoxicitY (40). 
e) The Value of Therapeutic Drug Monitoring: The evidence suggests 
that use of TDM to avoid toxic trough levels may decrease 
aminoglycoside ototoxicitY . 
.iil. NephrotoxicitY 
a) Mechanism: The role of aminoglycosides in the aetiology of renal 
failure is difficult to discern from numerous other insults to renal 
integrity in the seriously ill patient. Aminoglycosides are toxic 
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to the epithelial cells of the proxi mal renal tubule. The drug 
binds to the brush border PhospholiPid and is then taken up into t he 
eel 1 by Pinocytosis (6) (31). Intracellular fusion of the Pinocytic 
vesicles with primary lysosomes then occurs. Lysosomal 
PhospholiPase and SPhingomyelinase is inhibited resulting in 
lysosomal PhospholiPosis and accumulation of mYeloid bodies as well 
as release of toxic hydro lases into the cytoplasm (6) (31) . InJury 
is manifest by loss of the brush border microvilli followed by 
swelling and disruption of cellular organelles and then cell 
necrosis and sloughing into the renal tubules to form cellular casts 
(6) . The basement membrane is preserved and regenerative activity 
occurs when the insult is removed with full functional recovery 
being usual (3) (6). 
b) Clinical features Renal impairment typically presents as acute 
non oliguric renal failure within 5 - 7 days of the start of drug 
exposure. There is a marked decrease in concentration ability and 
glomerular filtration rate and increased serum creatinine levels (3) 
( 6) . 
c) Incidence A wide range of incidence of nephrotoxicity for 
aminoglycosides is reported. This is due to the absence of 
standard definitions for renal failure, the coexistence of multiple 
nephrotoxic factors in many patients, variable patient 
susceptibility to nephrotoxic factors and a poor correlation between 
renal creatinine and aminoglycoside handling. The serial assessment 
of renal function and nephrotoxicitY is complicated by changes in 
renal blood flow secondary to variation in cardiac output during 
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fever and infection. The resolution of infection decreases cardiac 
output and renal blood flow and the associated decrease in 
glomerular filtration may then be ascribed to drug toxicity. 
Furthermore most studies require patients to be on aminoglycosides 
for a minimum of seven days before changes in renal function are 
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consi dered relevant. This causes considerable bias towards 
selection of more seriously ill patients who are more likely to have 
deteriorating renal function due to factors relating to the 
underlying disease Process. The histological features of 
aminoglycoside t oxicity are those of acute tubular necrosis whi ch 
are indistinguishable from those of sepsis and shoc k. 
Ne phrotoxicity is usually defined for study purposes as an increase 
of serum creatinine of 43 umol/1 C0.5 mg%) above the base line 
and/or a decrease in calculated creatinine clearance of 50% or more 
that is associated with aminoglycoside use. Measurement of urinary 
casts, urine renal enzyme levels and B microglobulin levels to 
define renal damage is sensitive but lacks specific·itY (6) (28). 
The range of incidence of nephrotoxicity has been reported at 0.5 -
63% (6). Large Prospective studies have reported incidences of 
7.2% (44) and < 1% in 1640 patients with individualised doses and 
control led levels C15). 
d) Risk factors : 1) Drug related: Nephrotoxicity correlates to 
drug concentration in the renal cortex (31) which in turn depends on 
the extent of drug exposure and rate of uptake. 
Renal toxicity risk has been associated with total dose (28>, 
duration of treatment (16) C28) (44), exposure to aminoglycosides in 
the Previous 70 days (3) (16>, peak and trough levels (16) and peak 
level only (16). However, only the duration of treatment is a 
proven risk factor on multivariate analysis (44). There are 
conflicting reports that duration of therapy C37) and peak and 
trough levels (16) (44) are not independent risk factors for 
nephrotoxicitY. It is suggested that high trough levels may be more 
important as indicators rather than predictors of nePhrotoxicitY 
C 10) (39) (45) . 
A 1976 study (43) reported a higher frequency of nephrotoxicity with 
intermittent as compare to continuous therapy, However, animal 
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studies have subsequently shown that continuous infusion results in 
significantl y higher renal cortical levels for both amikacin and 
gentamicin t han s ingle daily inJection of the same dose (31) . 
Lower renal cortical levels for intermittent dose therapy was also 
repor ted fr om a clinical trial on patients Prior to nephrectomy 
(31) . It is thus likely that less frequent administration of larger 
doses results in less renal cortical drug accumulat ion . The renal 
toxicity of currently used aminoglycosides i.e. amikacin, 
gentamicin, tobramycin and netilmicin is generally bel i eved to be 
equivalent C3) C28) C37). However there is an experimental basis f or 
claims of variable drug toxicity. Renal tubular cell upta ke 
kinetics have been described in one report as linear for amikacin 
but saturatable for gentamicin, tobramycin and netilmicin (16) while 
another study (31) reported linear uptake for tobramycin, 
in termediate uptake for amikacin and saturatable uptake for 
gentamicin and netilmicin. It is possible that the uptake pattern 
may have a significant influence on nephrotoxicity if larger doses 
are administered less frequently to achieve the same daily dose of 
drug, 
2) Non drug related: Increased age Predisposes to aminoglycoside 
nephrotoxicity (3) (16) (37) (39) (44). 
Animal experimentation suggests decreased risk in females (37). 
Some clinical studies report an increased risk in females (16) (28) 
(39) but multivariate analysis (44) suggests that males may be at 
increased risk. 
Shock and dehydration are risk factors for nephrotoxicity (3) (28) 
( 3 7) C 3 9 ) C 44) . 
Infection has been reported as a significant risk factor (3). 
Accurate assessment is difficult because resolution of fever results 
in decreased renal blood flow and glomerular filtration rate and 
this Phenomenon cannot easily be distinguished from drug related 
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effects. 
Earlier studies (3) (44) suggested an increased risk of 
nephrotoxicity in Patients with compromised renal function. More 
soph i st ica ted studies using multivariate analysis and maintaining 
dru g levels within a therapeutic range support the concept that 
hi gher pre administration GFR results in increased exposure of 
target tubular cells to the drug in glomeruler filtrate. 
believed to enhance nephrotoxicity (1 6) (38) (46). 
This is 
Hepatic dysfunction may cause renal vasoconstriction with decreased 
ren al blood flow and elevated Plasma renin levels. Liver disease 
ha s been proposed as a significant risk factor for nephrotoxicity i n 
several studies C 16) (37) (39) (44) (46). 
Data on additive nephrotoxicity caused by concomitant use of other 
drugs remains conflicting. Loop diuretics, first generation 
cephalosporins and vancomycin may enhance aminoglycoside 
n e Ph r ot ox i c i t y C 2 8) ( 3 9) ( 44) . There i s a w i de 1 y he 1 d be 1 i e f that t he 
nephrotoxicitY of cyclosporin, acyclovir and amphotericin B may be 
additive to that of aminoglycosides. However, some studies (37) 
have failed to prove a significant correlation between the use of 
furosemide and cephalothin and risk of nephrotoxicitY. 
The drug and non drug related correlates of aminoglycoside 
nephrotoxicity remain uncertain. This is especially evident in the 
failure of several attempts to develop a predictive algorithm for 
nephrotoxicity (6) (46). 
e ) The value of TOM : A retrospective case controlled study on 313 
Patients (44) demonstrated a significant decrease in gentamicin 
nePhrotoxicity with strict drug level control. 
A randomised prospective double blind study comparing the use of 
tobramycin and gentamicin in 214 patients (37) demonstrated a 
decreased risk of nephrotoxicity when drug levels were maintained 
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within a therapeutic range, This beneficial effect wa s most 
significant for patients wi th impaired renal function. 
A study of 103 cases of amikacin therapy in granulocytopaenic 
patients in whom drug levels were controlled revealed no evidence of 
increased nePhrotoxicitY despitf the use of significantly higher 
doses to achieve target drug levels (47). 
A review article on aminogl ycoside toxicity (6) concluded that TOM 
results in a significant dec rease in gentamicin nephrotoxicitY. 
However, careful monitoring of serum levels does not exclude the 
risk of nephrotoxicity (16) . 
iiil Conclusion 
The most important determinants of drug toxicity are total dose and 
duration of therapy, This knowledge is of limited therapeutic 
value because these parameters cannot be prospectively controlled so 
as to decrease toxicity . Drug levels are however readily available 
and drug dose and dose frequency can be altered. The correlation 
of trough levels with toxicity is important because control of 
l evels can present a therapeutic goal . The value of Pea k l evel 
con trol for decreasing aminoglycoside toxicity is less well 
established . Single daily dose would also appear to minimise 
toxicity . 
In this study control of trough levels was implemented with an upper 
limit of 6 mg/1 for amikacin being used. The upper limit f or pea k 
levels was set at 40 mg/1. Due to concern about therapeutic 
efficacy, single daily dose therapy was not used except in patients 
with impaired renal function. 
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:.......S.... ~ THERAPEUTIC EQ.LE QE DRUG. MONITORING 
1 • 5. 1 . MEAS! IRING AMINOGL YCOSIDE LEVELS, 
Th e ~s e of rapid and accurate aminoglycoside assays has made drug 
monito ~ing possible. Aminoglycoside levels were originally assayed 
usin g a slow and cumbersome bioassay. This was replaced by 
accurate but labour intensive high performance liquid chromatography 
and gas liquid chromatography methods. Clinical assays currently 
us e either the radioimmunoassay or fluorescent antibody immunoassay . 
The fluorescent antibody method is more popular because it yields 
good interassay correlation and minimal bias and avoids radiation 
exposure C 3) . 
Th e fluorescent polarization immunoassay CTDX ABBOTT) (48) is a 
widely used assay system which utilizes a fluorophore comprising the 
specific aminoglycoside bound to a fluorescent dye. This complex is 
excited by a blue (485 nm) light from the polarized light source, 
and emits a green (525-550 nm) light on return to the steady state. 
The polarization of emitted light depends on the Position of the 
fl uorophore at the time of Photon emission. If the fluorophore is 
bound by a large antibody molecule it can no longer rotate freely 
and the emitted green light is in the same plane as the blue 
excitation light i.e. polarization is retained. If the fluorophore 
is unbound it is free to rotate and can emit the green light in a 
any plane i.e. polarization is lost. The TDX competitive binding 
method al lows tracer label led .aminoglycoside and patient serum 
aminoglycoside to compete for binding sites on a fixed number of the 
anti-aminoglycoside antibody molecules. Since emitted light 
polarization increases as molecular size increases and molecular 
size is dependent on antibody binding, a precise relationship 
between the drug level in a specimen and polarization can be 
established by measuring the polarization of calibration specimens 
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of known concentration and establishing a standard curve. 
Polarization measurements from specimens of unknown drug 
concentration can then be correlated with drug levels. 
1 s? EMPIRIC .D.E..L1.G. .LLS.E..... 
The availability of rapid and reliable drug assays allows 
therapeutic monitoring of drug levels. It was soon demonstrated 
that use of the mg/kg dose recommended by the drug manufacturers 
resu lted in unpredictable and often non therapeutic drug levels (3) . 
Empiric ( trial and error) therapy in 86 patients without organ 
failure and who did not require ICU admission C8l resulted in 21% 
toxic and 36% sub therapeutic levels. A randomised prospective 
st udy of 40 acutely ill patients (49) compared clinician estimates 
of dosage requirements with the calculated dose using a nomogram and 
the predictions of a kinetic program. Use of the empiric method 
re sulted in 20% subtherapeutic peak and 70% toxic trough levels 
as compared to 85% of trough levels and 90% of peak levels in the 
therapeutic range for the kinetic method. Nomogram based therapy 
was not significantly more accurate than the empiric method. 
A survey of aminoglycoside levels achieved in the Isolation Unit of 
the Department of Haematology at Groote Schuur Hospital was 
Performed in January 1990 (Groenewald P. et al personal 
communication). No attempt was made to supervise or monitor drug 
administration or specimen sampling which was performed routinely by 
nursing staff . Results can thus not be used .for comparison with 
other methods of TOM but are valuable in demonstrating the 
Performance of the empiric method in this Unit. Subtherapeutic pea k 
levels (< 20 mg/1 ) occurred for 49% of levels and 16% of trough 
levels were toxic (>6 mg/1). Only 46% of paired peak and trough 
l evels were therapeutic ( Peak 30 +/- 10 mg/1 and trough not >6 
mg I l) . 
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Empiric aminoglycoside therapy by experienced medical staff does not 
consistently achieve therapeutic and non toxic drug levels. 
J .5.2. NOMOGRAMS. 
Patient physiological parameters including age, sex and calculated 
creatinine clearance may be used in an algorithm to calcul~te 
individual aminoglycoside requirements. This method depends on 
several assumptions which are not necessarily valid for 
aminoglycoside kinetics especially in infected patients . Vd is 
presumed to be a constant and predictable fraction of actual and/o r 
ideal body weight. Drug clearance is calculated from the serum 
creatinine or creatinine clearance value. 
Although nomogram predictions have been shown to achieve up t o 85% 
accuracy for therapeutic levels in selected male patients under 50 
years old with no organ failure and treated outside of ICU (46J, 
general use in non selected populations has proved disappoint ing 
with achievement of only 48% therapeutic range peak with 30% toxic 
trough levels reported in one review (3) . A further study reported 
the achievement of therapeutic peak and trough levels in only 30% of 
cases (50) . 
Nomograms retain a role for initial dose calculation in the Bayesian 
kinetic prediction programs. 
1 .5.4. Il::iE KINETIC PREDICTION MODEL. 
Measured drug levels are used to· ·construct a concent rat i 011 - ti me 
curve . Kinetic parameters for the individual are derived and dose 
requirements to achieve target of drug levels can then be 
calculated. Several individualized kinetic prediction models 
have been developed. This discussion is limited to two, that of 
Sawchuck and Zaske CSZ) and the Bayesian statistical method. 
Calculation of a required dose from derived ki netic parameters 
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utilizes st and ar d ki netic fo rmulae. 
i2.. I.he Sa wc hucl Zas ke ~ethod, 
This is based on a one compartment kinetic model with dru g level 
measurement being delayed to at least one hour after the start of 
infusion to avoid inaccur acies due to the initial dis t ri bution Phase 
(3) . The peak level achieved is largely a function of Vd and t his 
leve l is t hus an i mportant data point for Vd estimation . 
Measurement of a second level at approximately 1 .5X the usual drug 
ha lf l i fe Yields an accurate estimation of graph slope and thus drug 
clearance. Data po i nts in excess of 4 Per interval yield little 
additional information. No patient physiological parameters are 
required. The serum concentration -time data is fitted to a 
regression curve using a least squares analysis. The most accurate 
resul ts are achieved using computerized non linear regression 
analysis. 
Th e S-Z method has been well validated for several groups of 
Pati ents in numerous clinical trials and has made a considerable 
contri buti on to effective therapeutic drug monitoring. 
CiPolle et al (18) studied the clinical efficacy of indivi dual ised 
tobramycin therapy in 26 patients with serious Gram negative 
Pneumonia. Dosage requirements showed significant inter- and 
intrapatient variations with a range of 0.4 - 15.5 mg/kg/day. 
Optimal serum levels were achieved early in the treatment course and 
were well maintained. There was no nephrotoxicity nor clinical 
ototoxi citY. The authors concluded that the high clinical response 
rate of 88% was significantly influenced by the maintenance of 
therapeutic drug levels. 
Zaske et all (51) studied the use of the S-Z method for gentamicin 
therapy in 66 patients with severe burns complicated by Gram 
negative sepsis. Individualised therapy was shown to be a 
significant factor in the survival for the first episode of sepsis 
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with an improvement from 33 t o 64% using a historical control. 
Larger doses of drug were required in the ind ividua lized therapy 
group i .e. 7 .4 mg/kg/ d vs 3 - 5 mg/ kg/d. Wi de inter- and intra-
patient var ia t ion in dosage requirement was shown. 
Sveska et al (5 2) reported a ret rospect ive review of differences in 
outcome between individualized and non individualized aminoglycoside 
treatment of culture proven Gram negative pneumonia or sepsis i n 42 
patients. The authors concluded that individualized therapy is 
associated witr1 decreased mortality, a decrease in the rise of serum 
creatinine level above base li~e and decreased length of drug 
therapy and hospital stay. 
Denaro and Ravencraft C11) reported a prospective study to determine 
the prediction performance and therapeutic value of individualized 
drug therapy in 51 patieDts. The method predicted 79% of peak 
concentration values within 2 mg/1 of the target level of 8 mg/1 for 
tobramyc in and gentamicin and 82% of trough levels within mg/1 of 
target trough levels of 1mg/l. Significantly increased doses i.e. 
1 .5 - 2 X recommended, were required to achieve therapeutic levels. 
A wide variation in kinetic Parameters was reported, Vd 0.16 - 0.52 
1/kg and clearance 0.04 - 0.17 1/kg/hr despite normal initial serum 
creatinine levels in all patients. The authors concluded that 
individual kinetic parameter determination is essential for early 
achievement and maintenance of therapeutic drug levels. 
Reed et al (12) reported a prospective study on the use of 
nephrotoxic antibiotics in 166 patients in a surgical ICU. 
Significantly improved therapeutic peak level frequency was achieved 
for individualised therapy compared to a control grouP. Therapeutic 
gentamicin peak levels were achieved in 9% of controls as compared 
to 91% of individualized patients (P<0.005) with the corresponding 
figures for tobramycin being 27% vs 92% (P <0.0001). Critically ill 
patients required larger doses and longer dosage intervals than 
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gene r ally r ecommended . . Large intrapatient kinet ic var i ab i lit y wa s 
observed and the authors suggest a minimum of alternate day 
me as ur ement and ki netic prediction with dose adjustment as 
neces sary. The authors rejected the often stated be l ief that 5X 
dr ug t 1/ 2 i s r equired to achieve "a steady state" and measured 
levels after both the initial dose and immediately fo l lowing dose 
adju s tment. 
El -Sayed and Islam (49) compared non kinetic and kinetic approaches 
to individualisation of gentamicin dosage in 40 acutely ill 
patients. Use of the non kinetic method resulted in 70% toxic 
trough levels and 20% sub therapeutic peak levels, while the kinetic 
method CSZ> achieved an 85% therapeutic trough and 90% therapeutic 
peak 1 evel . 
.i.i1_ I.he. Bayesian Method. 
Bayes theorem converts prior probabilities into posterior 
probabilities by their interaction with likelihoods. Prior 
probability can be ascertained or estimated from retrospective 
observations in the specific population from which a subject is 
derived. In drug kinetic studies the prior probability is the 
known mean and standard deviation of kinetic parameters such as Vd 
and Cl. A new measurement or observation can then be used to 
es timate a revised value for the parameter which is then known as 
t he posterior Probability (53). 
Bayes theorem utilizes population and individual parameter 
measurements to obtain reliable estimates of individual kinetics 
(54) (55). Model initiation assumes that an individual is a typical 
member of a population with known kinetic parameters. This 
assumption is optimal prior to drug use because no information is 
available to estimate the patients individual variation from the 
mean parameters corrected for that individuals physiological 
variables such as age, weight, sex and creatinine clearance. 
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Measured drug levels at known times after administration of a 
specifi ed dose are used in an adapted Bayesian formula to adJust the 
prior probability distribution of an individuals parameter set and 
thus arrive at a revised or posterior distribution . This posterior 
distribution is then utilized as a Prior distribution for the next 
round of kinetic forecasting . Thus kinetic parameters are 
constar1tly re ·ised to mor~e closelY approximate the indiviaua l 's true 
kinetic values and to compensate for variations in parameters wit h 
time. 
Tt1e Bayesian mett1od thus adJusts estimates of kinetics after each 
measurement input so as to ma ximal ly utilize available populat ion 
and patient specific information allowing the estimate of individua~ 
parameters to move smoothly from those appropriate to a typical 
~ember of the sub population to those appropriate to an individual 
as informat~on on that individuals characteristics accumu l ates. 
The method has been computerized and several versions are available 
for use on a personal computer . The OPT program was used for thi s 
~t:Jdy (56 ) . Kinetic predictions are based on a one compartment 
open mode l . The parameters util ized are starting concentration at 
initi8lisat~on of the model, drug clearance and volume of 
d i stribution . First order kinetics are assumed and OPT is 
consiCered equally valid for steady and non steady state data . The 
Program has been validated for accuracy in several hospital 
populations C56) . 
~se of the Bayesian method based individualized drug therapy is 
well documented and comparison with the S-Z method has been 
reported . The following is a review of some available information. 
Burton et al (57) assessed the accuracy of a Bayesian method in 
Providing dosage regimens to achieve desired aminoglycoside 
concentrations in a Prospective study on 78 patients . The method 
performed well in _clinical Practise and was significantl y more 
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accurate than either the emp irical or nomogr am based therapy, The re 
was no significant difference between Predicted and achieved peak 
and trough levels using the Ba yes i an method for gent amic in and 
tobramycin. This was comPared with the nomogram and empiric methods 
by determining the ability to predict levels wit hin +/- 2 mg/1 for 
peak and +/-1 mg/1 f or trough values. The Bayesian method ach i eved 
the target for 86. 1% of peak and 86.2% of trough levels compared to 
63.9% and 75.9% for the nomogram and 33.3% and 66.7% f or empiric 
methods r espect i ve ly . 
In a prospective study in 13 patients (20) Chrystyn assessed the 
value of Bayesian analysis in optimizing gentamicin therapy from the 
time of commencement of treatment. The sampling time was at 1 hour 
and 4 hours after the start of the drug infusion. Results were 
equal in accuracy to those achieved with the S-Z method using three 
levels. This study concludes that a one compartment model using two 
drug levels gave results sufficiently accurate enough for clinical 
use. 
Lacarelle et al (58) evaluated a Bayesian method of amikacin dosing 
in ICU patients with normal or impaired renal function. The 
population kinetic parameters were derived from kinetic studies in a 
population undergoing treatment in the same unit. Bayesian estimates 
used peak and trough levels. The study concludes that the Bayesian 
method performance is accurate for both estimates of kinetic 
parameters and prediction of drug levels with both results and their 
95% confidence levels reported below: 
Bias CME) Cmg/1) 
Pree is ion CRMSE) 
Cmg / l ) 
- 0.03 C-0.68 to 0.60) 
2.69 (2.07 to 3.19) 
Jrou9h 
- 0 . 21 C -0 . 51 to - 0. 08) 
1.24 C0.9 to 1.5) 
Prediction precision was better for peak than trough levels. This 
4 1 
reflects the close relationship of peak levels to Vd which tend s to 
fluctuate less than the Cl which correlates more closely to trough 
levels . The one compartment model wa s found to functi on adequatel y 
and data routinely collected by unsupe rvised ICU nursing staff 
was reli able. 
at 0.35 1/kg, 
The mean Vd was higher than that general ly reported 
Rodvol d et al (59) reported on a retrospective evaluation of the 
predic t ive performance of a one compartment Bayesian forecasting 
program i n 30 ICU patients with stable renal function. This study 
demonstrates that the use of population kinetic data derived from 
ICU patients rather than the general patient population, results in 
significantly improved prediction precision with less bias. 
Replacement of general population data with ICU derived population 
data improved the achievement of therapeutic range levels from 80% 
to 100%. The use of conventional population data generally resulted 
in over prediction of peak and trough levels. There was no 
advantage in using "steady state" levels. Use of further levels in 
addition to peak and trough levels did not significantly increase 
the predictive value. 
Godley et al (60) compared the predictive performance of three 
microcomputer programs for gentamicin in a retrospective·study on 30 
patients. Equivalent performance was found for the three programs 
using peak and trough levels to predict levels five days later. 
Performance was matched by the use of the S-Z method. Bayesian 
methods were found to tend to over estimate drug levels while the S-
Z method was biased towards under prediction. One of the Bayesian 
methods was found to have equivalent prediction accuracy using only 
one level input. 
Bottger et al C42) compared the performance of the Bayesian and s~z 
methods in 19 critically ill patients. Both methods resulted in 
precise and unbiased predictions with the Bayesian method being more 
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precise f or ami kac in . The variati on in dose r equ irement for 
amikacin was 3.8 - 30.0 mg/kg/d. The authors noted that the maJor 
factor l imiting the predictive accuracy of currently available 
methods is the l a r ge and rapid intrapat i ent changes in kinetic 
parameters. 
A further comparison between the Bayesian and S-Z methods is 
reported by Denaro and Ravenscroft C61). 36 seriously ill patients 
were studied to compared the 4 level input S-Z method with the 
Bayesian method using trough and from 1 - 3 post infusion levels. 
Al l methods performed well except for use of the Bayesian model with 
only one level measurement which was not successful. There was no 
si gnificant difference between the S-Z method and the Bayesian 
predictions which used trough and 2.2 hr post infusion levels. The 
4 level Bayesian method yielded the most precise predictions. 
Bayesian methods tended to under estimate Vd and Cl resulting in 
l evel predictions which exceeded those achieved. 
iiil Selecting a ID..t:1 Method. 
The available data suggests that it is possible to achieve accurate 
ki netic predictions in clinical practise. This should allow 
dosage prediction and the consistent achievement of therapeutic drug 
l evels. It is also evident that the currently available methods 
have performance limitations imposed extrinsically by variability 
in kinetic Parameters and the potential for improvement of accuracy 
i s thus limited. Selection of a TDM method to be used depends on 
accuracy, efficiency and ease of application. 
The SZ and Bayesian methods can achieve equivalent predictive 
accuracy. While the Bayesian method can be used with fewer drug 
samples and a more flexible sampling regimen. the SZ method has the 
advantage of requiring no physiological data input. However lack of 
such input increases reliance on sample level accuracy with an 
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increased Po tent i al for maJor error should input data be i naccurate. 
Th e choice of optimal samPling time is more important for successful 
us e of t he Bayesian method. Peak level sampling at 1 hour allows 
the use of a one compa r tment model and yi e l ds the most va luab l e 
in put for estimation of Yd. Optimal sampling time for determ ini ng 
cl ea r ance is at 1 half life. This is not known in ad vanc e and a 
l evel at 1 esti mated half life after· the pea k level is tt1us used. 
Assessment of cost effectiveness is of increasing i mportance. Us e 
of the S-Z method usually incurs the cost of additional samples. 
The data processing equipment and personnel time use for both 
methods is equivalent. The overall cost effectiveness of TDM has 
been studied but no reliable cost effectiveness data from 
prospective controlled studies with appropriate dose and level 
con tr·ol is available (62). However, it is well establ i shed that TOM 
i s effective in maintaining drug levels therapeutic and non to xi c. 
Furthermore, performing aminoglycoside assays without TOM is of 
li mi ted value. Thus the indirect evidence is strongly i n support of 
the be li ef that TOM is cost effective in improving the quality of 
patient care (63). 
This study used a Bayesian method and two aminoglycoside levels per 
ki netic estimat i on. 
~ ANTIBIOTIC THERAPY .IN Il:iE. FEBRILE NEUTROPAENIC PATIENT. 
Infection is the principle cause of morbidity and mortality in the 
neutropaenic patient. A maJor contribution to improved treatment 
results has been effective antibiotic therapy, The definition, 
aetiology and treatment options for febrile illness in patients with 
malignancy and neutropaenia are reviewed so as to examine the role 
and requirements for aminoglycoside therapy in this population. 
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Both malignant disease and the currently used treatment moda1ities 
r esu l t in bone marrow suPPression and neutropaenia. This r es ul~s 
in profound immune compromise and the increased r i sk of overwhe l ming 
in fect i 011. The incidence of infection increases s i gnificant ly when 
the combined neutroPhil and band form count drops below 1 X 10A9/l. 
Ri sk of infection increases with decreasing neutroPhil counts and 
~i fe t hreatening bacteraemia occurs most frequently when counts dr op 
below 0.1 X 10A9/l (64), when the rate of decrease is rapid and ~f 
ileut ropaenia persists for longer than 14 days (36) (65) (66). 
Fever i s the only reliable indicator of infection in the 
neutroPaenic patient. The definition of fever is arbitrary, but 
The National Cancer Institute diagnostic criteria (66) are 
re presentative of current practise. Fever is considered significant 
i f e i ther 1) 3 oral temperatures exceed 38 degrees C during a 24 
hour period or 2) a single temperature over 38.5 degrees C occurs. 
Infection in the neutropaenic patient has a characteristic 
distribution with more frequent involvement of the peridontal and 
Pharangeal areas, facial sinuses, oesophagus, colon, rectum and s kin 
and PL.:ncture sites. Pne·umon i a and septicaemia are the most common 
causes of death (36). Neutropaenia results in decreased 
in flammatory response to infection which delays both early clinica l 
diagnosis and localization of infection sites. The infecting 
organisms multiply and spread more rapidly (36) resulting in 
overwhelming sepsis and rapid ~emise. Neutropaenic patients have a 
significantly increased risk of infection with Gram negative aerobic 
bacilli and StaPhlococci complicated by the later development of 
fungal or bacterial superinfection. The aetiology of infection in a 
Particular group of neutropaenic Patients depends on their 
endogenous flora, 50% of which is usually hospital acquired at the 
time of infection C66). Organism distribution is largely 
;n+1 ,1 c , nrl""\ri h ,, '""....,~,,~.:1.:f""\,..., ""',....,.....: _ _.._, --.J.....!1......!-.L.!- · ·---- --.L.L---- TL--
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influence of antibiotics is demonstrated historically by the ongoing 
changes in the pattern of infective organisms in febrile 
neutropaenic patients throughout the period that antibiotic therapy 
has been available . In the pre- antibiotic era the most common 
pathogens were Streptococcus py.ogenes and Pneumococcus . Penicill in 
use significantly increased Staph . aureus isolates and the 
subsequent development of anti staphylococal penicillins and 
cephalosporins in the late 1960s was associated with a significant 
increase in the prevalence of Gram negative aerobic infection . Use 
of aminoglycosides and increasingly broad spectrum 8-lactams in the 
1970s resulted in the emergence of an increasing problem with Gram 
positive cocci including StaPh . aureus and epidermidis , group D 
Streptococci , B haemolytic Streptococci as wel l as diPtheroids and 
anaerobes . The spectrum of Gram negative infection also shifted t o 
include more isolates of citrobacter , acinetobacter and enterobacte r 
(67). The increased incidence of Gram positive cocci and especia lly 
staphylococc i may partly be ascribed to monotherapy with 
cephalosporins (68) , Prophylactic use of quinolones (66) and 
increased use of indwelling vascular access devices (68) . 
Febrile episodes are clinically ascribed to and treated as infect ion 
in neutropaenic patients although 25-40% (36) (66) of cases have no 
microbiological or clinical basis for this diagnosis . Many of these 
febrile ePiiodes may be due to transfusion reactions, drug fever, 
cell lysis following chemotherapy and fever associated with t he 
underlying malignancy . The overall rate of isolation of an 
in fective cause of fever f rom blood or other sites ranges from 6-40% 
(64) (69) . This low rate of organism isolation implies that reported 
isolates do not necessarily represent the cause of infection in this 
population . 
No data is currently available on the spectrum of isolates fr om the 
Unit in which thi~ study was performed . Use of published data is 
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t hus requ i red for the planning of therapy, The European Organ i zat ion 
fo r Resea rch on Treatment of Cancer CEORTC) has Published three 
l arge multicentre survey based reports on the microb i ological 
i sol ates fr om neutropaenic Patients with fever. The EORTC I trial of 
1978 reported a 20% incidence of documented bacteraemia in febr i le 
patients with malignancy and neutropaenia. These were equally 
div i ded between Gram positive and negative isolates (64 ) . The EORTC 
III trial of 1982 revealed an increased proportion of Gram negative 
i solates at 57%. Later reports especially those from North America 
r eveal a greater frequency of Gram positive organisms averaging 60% 
(70). However mortality rates for Gram positive infection remains 
1 ower at 5 -23% ( 36) ( 70) compared to a 30 - 40% morta 1 i ty for Gram 
negative infections (70) . 
Empiric therapy should thus include effective cover for Gram 
negative infection which remains a serious threat to life. 
J ,6.1. THERAPEUTIC GOALS. 
Neutropaenic patients with fever require prompt therapy, Empiric 
antibiotic therapy is accepted universally as a maJor factor in 
improving survival although this has not been verified in a 
controlled study (71). The historical precedent of the very poor 
results when commencing antibiotic therapy only after documentation 
of infection (64) is accepted as adequate proof of efficacy for 
current practice. 
Al though antibiotics have an important role, the most significant 
survival and prognostic factor in this group of Patients is recovery 
of adequate leucocyte function (72) (73). Severe neutropaenia is 
a maJor risk factor for treatment failure caused by superinfection 
(36) . 
Optimal use of antibiotics depends on rapid delivery of adequate 
amounts of the correct drug to the site of infection while avoiding 
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undue toxicity. Knowledge of the type of infecting organism and 
its in vitro sensitivity is rarel y available at the initiation of 
therapy, Empiric antibiotic therapy should thus cover the most 
probable infected organisms while minimizing disturbance of 
colonizing flor a and the development of resistance. Combination 
therapy using an extended spectrum 8-lactam and aminog lycosi de is 
widely used but not universally accepted therapy, 
1 .6.2, SYNERGISTIC ANTIBIOTIC THERAPY, 
Use of synergistic combinations has several advantages: 
1) Provision of more efficacious and extended spectrum cover. 
2) Prevention of development of resistant organisms. 
3) Allows use of lower drug doses with reduced toxic potential. 
i2.. .D.c.u.9. Effectiveness. 
The value of empiric combination therapy with extended spectrum B-
lact am and aminoglycoside combinations is well established with no 
particular combination being shown to have a significant advantage 
(67). Gram negative infection mortality rates of 60 - 90% in the 
1950s has been reduced to the current levels of 10 - 30% (67). The 
enhanced effect of combination therapy is especially well 
demonstrated for persistently neutroPaenic patients in whom survival 
has increased from 0% to 44% (71). 8-lactams in combination with 
aminoglycosides have been shown to increase the serum bacteriocidal 
activity from 1 :4 to 1 :16 with a concomitant improval in favourable 
outcome from 49 -80% (36). Combination therapy may be effective 
against organisms resistant to either the B-lactams or 
aminoglycoside used alone. In one study (36), 70% of Staph. 
epidermidis resistant to both 8-lactams and aminoglycosides were 
susceptible to the two drugs used in combination. In vitro studies 
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have shown enhanced Staph. epidermidis killing even at l ow 
ami noglyco s i de levels with a decreased incidence of emergence of 
r esis tance (36 ) . Group D streptococci (Enterococci) may be 
resi s tant t o B-lactams by virtue of decreased affinity of a lower 
molecular weight Penicillin binding protein. Aminoglycosides are 
c l inically ineffective because bacteriocidal drug concentrations 
cannot be achieved in vivo. However, a combination of 8-lactam and 
aminoglycoside results in sufficient disruption of bacterial cell 
walls to allow high intrabacterial aminoglycoside levels which are 
rapidly bacteriocidal (2) (74). Syner~gistic action against 
Pseudomonas has been demonstrated but the mechanism of the 
antibiotic effect remains uncertain (74). 
Synergism between different 8-lactam antibiotics is currently 
subJect to intense research. While a degree of synergism does occur 
for some combinations, data remains less certain than that for the 
B-lactam aminoglycoside combination and the Potential for drug 
antagonism exists (73). 
iil. Antibiotic Resistance . 
There is some experimental and clinical evidence that combination 
therapy prevents or retards the emergence of antibiotic resistant 
strains (36) (72). This has become evident in trials of extended 
spectrum B-lactams as monotherapy for fever in neutropaenic 
Patients during which resistant Gram negative organisms have caused 
serious nosocomial infections. Resistance may be due to either the 
production of induceable cephalosporinase or plasmid mediated 8-
lactamase. Animal studies have shown that the combination of 8-
lactams with aminoglycosides limits the emergence of resistance. 
However a disturbing finding has been that some 8-lactam resistance 
Plasmids also coded for aminoglycoside resistance (75). 
Aminoglycoside only empiric therapy has been attempted, but had a 
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50% treatment failure rate Princi pa lly due to the rapid development 
of resistant organisms. (43) (67). 
Imipenem is the latest agent to be used as monotheraPY and aquired 
resistance among Pseudomonas aeruginosa has emerged as a si gnif icant 
problem (67). 
iiil. Toxicity, 
The Principal motivation for the development of alternative non 
aminoglycoside containing regimens has been the problems of 
aminoglycoside nephrotoxicity and ototoxicitY. Concern has 
increased with the more frequent use of agents such as amphotericin 
8, vancomycin and cyclosporin A which are also potentially 
nephrotoxic. 
Several theoretical potential adverse effects of the 8-lactam 
aminoglycoside combinations have been researched. No additional 
nephrotoxicity has occurred with the addition of third generation 
cephalosporins to aminoglycoside therapy (36) (74). Tr1e chemical 
inactivat ion of aminoglycoside by 8-lactams has also never been 
demonstrated as a significant in vivo problem (36) (74). 
Significant toxicity does occur with 8-lactam combination therapy, 
A combination of moxalactam and PiPricillim resulted in a 48% 
incidence of detectable coagulopathy and 1% nephrotoxicity compared 
to 9% nephrotoxicity and 21% ototoxicity for a combination of 
moxalactam and amikacin reported in the same study (73). 
J ,6,3, DURATION QE THERAPY, 
The optimal duration 9f antibiotic therapy in febrile neutropaenic 
patients remains uncertain. Current dogma asserts that antibiotic 
therapy should not be stopped until neutropaenia has resolved. This 
i s largely based on the results of a single prospective controlled 
study with limited clinical information and in which ant i biot i c 
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theraPY wa s stoPPed after 24 hours of apyrexia (76) . There was a 
relapse of fev er in 41% of Patients most of whom responded we ll t o 
re sumpti on 0f antibiotic therapy. Further exposure to antibiotic 
was avoided in 59% of patients despite the cessation of therapy 
aft er a ve r y short Period of apyre xi a. There is a lso no good 
evidence that ongoi ng use of empiric ant i biotics in patients with 
persistent neutropaenia and reso lved fever is effective in 
prevent ing furt her febrile episodes C68). Prolonged use of broad 
spectrum antibiotic therapy increases the risk of toxicity, 
super in fection, the development of resistant organisms, drug fever 
and drug allergy (76). It may thus be reasonable to propose 
ces sation of therapy at 7 days after the last febrile episode in a 
pers i stently neutropaenic patient (76). 
The Patients in this study were treated according to Unit Protocol 
with antibiotic therapy being stopped when the neutrophil count was 
above 1 X 10A9 /1 and the patient had been apyrexial for at least 48 
hours . 
1 I 6 I 4 I J.fil. QE Il2t1.. 
Finley et al (47) have reported a comparison of standard vs 
pharmacokineticaly adJusted amikacin dosing in granulocytopaenic 
patients. A non Bayesian kinetic model was used The comparison was 
done sequentially on different patient groups and was thus neither 
r andomised nor fully controlled. The authors concluded that TOM was 
a significant factor in the safe use of increased doses of amikac in 
which contributed to a improval in response rate from 56 to 80%. 
1 ,6.5. CONCLUSION. 
Optimal antibiotic therapy for the febrile neutropaenic patient with 
haematological disease is not yet established. A maJor limitation 
to therapeutic efficacy remains the constant evolution of microbial 
5 1 
an t i b io : ~c r es i sta ric e. Ori the basis of availab l e data H i s 
Propos ed t hat febr il e episodes are currently best treated by ea rly 
ini t i at ion of therapy with an empiric combination of a t hi rd 
generat i on cepha l ospo r in or extended spectrum peni c i ll in wi t h an 
amino gl yc oside. Furt her changes in therapy depend on r es ul ts of 
rTii crob i al i rwest i gations and clinical response. Opt ima l 
aminog1yc osi de therapy can on1y be instituted and ma i nta i ned by 
effective use of TOM. However experience in the use of T0M i n t his 
populat i on is limited and no studies using Bayesian models have been 
r eported. 
A further contribution to decrease toxicity is limitation of the 
duration of therapy to the shortest period possible. There is no 
evidence to support the continued use of antibiotic therapy in 
patients who have become afebrile until the resolution of 
neutropaenia. 
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To eva l ~ate the use of the OPT Bayesian pharmacokinetic Predictive 
Program for estimation of amikacin dose requirements in febri l e 
neutropaenic patients with haematological disease. 
METHODS. 
l......l PATIENT SELECTION. 
The study was conducted in the Iso 1 at ion Unit of the Depart merit of 
Haematology at Groote Schuur Hospital CGSH) and the University of 
Cape Town. This is a referral centre for the Cape Province and is 
t he only Unit offering bone marrow transplantation CBMT) in this 
r·egi on. 
Sequential admissions satisfying basic selection criteria were 
enrolled as study subJects. All patients were admitted for 
~n vestigation or treatment of an underlying haematolog ical disorder, 
had a febrile episode satisfying Protocol criteria and become 
neutropaenic at some time during amikacin therapy, Fever was 
defined by the Unit treatment Protocol as a temperature exceeding 38 
degrees C for longer than 6 hours or a single spike of 38.5 degrees 
C that could not be attributed to drug administration or a 
transfusion reaction. Neutropaenia was defined as a count 
including band forms) of less than 1 X 10"9/l 
~ INITIATION QE TREATMENT. 
The initial amikacin dose was decided empirically by the attendant 
medical staff. No attempt was made to influence the initial dose 
used. 
.3.........3... .D.R.U.G. ADM INISTRAT ION. 
Ami kacin su lphate (Bris tol ) was administered intravenoGsly diluted 
in 50ml of e i t her normal saline or 5% dextrose water. Solutions 
we re made up Just Prior to use by the Sterile Unit of the hospital 
pharmacy during the day and by the Unit nursing staff at nigh t and 
on weekends. The drug was infused through indwelling central venous 
catheters or peripheral cannulas over a Period of 30 minutes . 
Admi nist rat ion ra tes were either controlled by electronic dr op 
counters or closely monitored by nursing staff. After completion of 
the infusion the administration set was flushed with 50 ml of saline 
with heparin to ensure complete delivery of the dose. 
3-...iL.. BLOOD SAMPLING. 
Blood specimens for peak level assay were taken at exac tly one hour 
after the commencement of drug administration. Sampling was done 
either through the non administration lumen of the i nd wel ling 
cen t r al venous catheter or by a peripheral veniPuncture. A second 
level was taken in the first dose i nterval . The optimal time for 
this was considered to be 3 hours after the onset of the infusion, 
but any level taken in this interval was considered an acceptable 
alternative. Specimens were collected in glass vacuum tubes 
(Vacutainer) and refrigerated at 4 degree C until assay which was 
done wi th in 12 hours . . Storage of samples at this temperature UP to 
48 hours did not affect assay levels when assessed separately for 4 
extra specimens taken during this study . 
.3......5...... AMIKACIN ASSAY, 
Assay was performed in a routine manner by the techni cal staff of 
the Department of Microbiology at GSH using the Abbott TDX polarized 
florescent antibody method. The instrument was recalibrated Prior to 
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the start of the study and t hereafter at one monthly intervals. The 
medium control (value= 15.0 mg /1 ) was run with each batch of 
amikacin assays performed and the results recorded. The assay has a 
lower limit of sensit ivity of 0.8 mg/1, this being considered the 
smallest value that can be d istinguished from O wit h 95% confidence 
(48) . Values of < 0.8 mg/1 were entered as 0.4 mg/1 for the Purpose 
of kinetic parameter determination . 
.3.......6..... PHYSIOLOGICAL DATA. 
Pati ent height and weight were routinely measured on admission by 
the Unit nursing staff. Serum creatinine is measured routinely on 
admission and then at least 3 times a week. Assays are done by the 
Department of Chemical Pathology at GSH using either a Technicon 
SMAC or Astra Beckman automated analyser both of wr,ich utilize the 
Jaffe Picric acid method. 
~ KINETIC ANALYSIS, 
Details of age, sex weight, height, serum creatinine level, amikacin 
dosing history and the two initial levels attained were entered into 
a IBM compatible PC loaded with the OPT version 5.1 software package 
(Clydesoft) used under licence in the Department of Pharmacology, 
Initial kinetic parameters were calculated for each patient. These 
were then used in an additional section of the program to predict 
the consequences of various dosage regimens. Estimates of required 
dose and dose interval were entered by the operator and the 
predicted resultant peak and trough levels calculated using the 
kinetic estimates derived from the Bayesian model. Dose size and 
fr equency were then altered by the operator until predictions 
satisfying the criteria of a peak level of+/- 30 mg/1 with a trough 
level not exceeding 6 mg/1 were achieved. The dose regimen was thus 
not directly derived by OPT but by an operator using an iterative 
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process . This system allows for increased flexi~ilitY but does mean 
that prediction accuracy cannot be measured again s t a st anda rd 
l evel . 
Dose changes were limited to multiples of 50 mg and the dosage 
intervals to 6, 8 , 12 , 18 or· 24 + 6x hours . 
.i....8..,_ THERAPY MONITORING. 
The selected dosage regimen was implemented within 24 hours of the 
initiation of therapy, Amikacin levels were then assayed twice 
weekly according to Unit protocol and more frequently if there were 
clinical features or biochemical evidence (serum creatinine inc,ease 
of 30 mg/1 above baseline> of renal function impairment. Trough 
levels were measured 5 minutes before the next dose and peak levels 
1 hour after the start of adm i nistration of the dose C given over 30 
minutes). Each set of measurements was added to the computer da~a 
file and the OPT program used to re estimate the individuals kinetic 
parameters. OPT uses all available data with a time weighting 
method giving an increased value to more recent data. 
The separate program contained in the software package was then used 
to Predict the required dosage regimen. The new dosage regimen was 
implemented for the drug dose following that in which levels had 
been taken. 
~ PREDICTION ACCURACY, 
Accuracy was measured by comparing Predicted with achieved results. 
Bias was measured by calculating mean error CME> and precision by 
calculating mean absolute error CMAE) and root squared mean error 
CRMSE) . 
The method would be considered valid if the 95% confidence interval 
(Thompson's test) for mean error included O and the MAE and RMSE 
were < 8 mg/1 for peak levels and <4 mg/1 for trough levels. These 
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criteria are consistent with those used in Previ ous studies (11J 
(57) (58) (59) which use < 2 mg/ l for peak and < 1 mg/ l for trough 
respectively for gentamicin and tobramycin . The predictions were 
further assessed by calculating the Percentage of drug levels witr:in 
the therapeutic range when the predictive method was appropriately 
used. 
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The OPT ~inetic Prediction method was implemented for entire 
course of ami kacin us e i n 10 sequential admiss ions to the Uni t 
requiring such therapy according to treatment protocols from 10 !t •- ,c V'-A l I'-' 
1990 to 27 August 1990 . 
Patients population studied represents a wi de range of physio~oGica 1 
and pathological parameters as shown in table 1. 
TABL E 1 . 
Patjeo :t Aili;_ -5.e..:i tiejgb:t Qj~ease Serum crea:t jni ne t:lewt rQ 2b i J 
(yrs ) (kg) Init i al Maximum Int. Min. 
Cumol /1) X 10A9/l 
1 ) 16 M 54 APL 61 1 71 0. 13 0.03 
2) 1 5 M 54 AA 50 77 0.02 0.02 
3) 46 F 56 AML 97 97 0.00 0.00 
4) 47 F 53 Myeloma 47 69 0 .05 0 . 05 
5) 43 M 62 AML 85 102 0.02 0 . C'.2 
6) 34 F 57 MDS 71 80 0.63 0.08 
7) 19 M 58 ALL 73 73 0.40 0. 16 
8) 60 M 58 CML 83 136 5.60 0.00 
9) 1 5 F 53 AML 58 66 0.08 0.08 
10) 26 M 68 HL 66 1 51 0.03 0.0 ; 
ALL = acute lymphoblastic leukemia 
AML = acute myeloblastic leukemia 
APL = acute promyelocytic leukemia 
CML = chronic myeloid leukemia 
HL = Hodgkins lymphoma 
MDS = mye lodysplasia 
Int.= count at initiation of amikacin therapy 
Min.= lowest count during period of amikacin therapy 
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:~eatment of t he unde rly ing disease i n 9 patients wa s by 
c~emo t ~era py r egimens acc ordi ng to established prot oco l s. Pat i ent 6 
rec e ~v ed no spec if ic therapy, Three Patients (numbers 2, 4 and 10 ) 
und e r we nt bone marrow transp l antation. There was one pat i ent deat h 
durin ~ t he s tudy , pat i ent 1 failed to respond to chemot herapy, 
d=ve l oPed dis semi nated intrava scular coagu l ation and sub sequent 1y 
acut e r espi r at 0ry di st r ess syndrome and died in mult i - orga n fa il ure. 
~ AMIKACIN THERAPY, 
4, 7, 1 , DJlli.G SAMPLING, 
In i t i al sampling at 1 hour after the first dose was achieved in a l l 
10 patients. A second level within the first dosage interval was 
obta i ned in 9 cases with 1 Patient ( number 9) having the second 
l evel available onl y after the second dose. The second level of t~e 
ini tial assay pair was taken at an optimal 3 hours after initiation 
of the drug infusion i n 5 cases C Patients 5, 6, 7, 8 and 10 ) . 
4, 1 ,2, I2RUG. ASSAY. 
A total of 38 batches of TDX assays was performed. The median 
control had a mean + / - SD assay value of 14.7 +/- 0.5 mg/1 with a 
range of 13.9 - 15.6 mg/1. The manufacturers recommended range for 
th i s va l ue is 15 +/- 1.5 mg/1. (Abbott TDX Kit manual) 
a ,2,3, KINETIC PARAMETERS, 
The individual values are tabulated in appendix 1. These allow 
estimation of the intrapatient changes in kinetic parameters during 
therapy, A significant degree of variation during therapy is noted 
wi th a maximum percentage change from mean value of Vd of +55% in 
patient 1 and for Cl of +65% in patient 8. 
Mean and SD values for each Patient are summarized in table 2. The 
average mean+/- SD of 305 +/- 48 ml/kg for Vd lies within one 
standard deviation of 270 +/-60 ml/kg for amikacin reported in 
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TABLE : 2 PATIENT KINETICS 
PT KO Vd (ml/kg) SD Cl (1/hrl SD Cl (ml /kg/min l SD T 1/2 (hr) SD 
----- ---------- ------ --------- ---- -------------- ---- ---------- ----
1 432 .0 121. 0 4.9 1. 6 1. 5 0.5 4.5 2.7 
2 299 .0 29 .0 8.5 3.6 2.6 1.1 1.6 0.7 
3 272. O 30 .0 4.6 0.6 1. 4 0.2 2.3 0.3 
4 285 .0 26 .0 5.6 1.4 1:7 1.1 2.0 0.5 
5 230. 0 20 .0 4.6 0. 7 1. 2 0.2 2.2 0.2 
6 266.0 67 .0 7.9 1. 5 2.3 0.4 1. 4 0.5 
7 327 .0 71 . O 8.7 2. 7 2.5 0.8 1.6 0.5 
8 337 .0 52 .0 3. 4 1. 4 1. 0 0.4 3.6 1. 7 
9 266 .0 20 .0 5.5 0. 6 1. 7 0.2 1.8 0. 1 
10 339.0 47 .0 7.7 2.2 1. 9 1. 5 1. 9 1.1 
••••• z••••••••• =••••• ••••••••• •••• aaaa•••••••••• =••• •••••••••• •••• 
Average: 305 . 3 48.3 6.1 1. 6 1. 8 0. 6 . 2.3 0.8 
TABLE: 3 PREDICTION PERFORMANCE 
PT KO DOSE KEAN PK KEAN PR KE KAE RXSE KEAN TR KEAN PR KE KAE RXSE 
----- ----- ------- ------- ----- ----- ----- ------- ------- ----- ---- ----
1 11. 9 34 .6 28 .1 1. 2 6.9 7.9 8.7 3.8 4.9 4.9 6.0 
2 11 . 3 29 .3 26.6 2. 7 4.5 5.5 2.0 1. 2 0.8 1. 0 1. 4 
3 9.3 26.0 27 .4 -1.4 4.0 4.6 1. 3 1. 0 0.3 0.7 0.9 
4 11. 5 30.3 31. 8 -1. 5 4.3 5.6 1. 2 0.6 0.6 0.7 0.8 
5 9.1 28.1 34.8 -6 .7 6. 7 6. 9 2.9 3.8 -0.9 1. 4 2.4 
6 9.1 30.6 22.4 8.2 8.2 8.5 2.4 1. 0 1. 4 2.3 2.5 
7 11. 7 36.6 26 .2 10.4 10.4 10.8 2.8 1. 4 1.5 1. 5 1. 9 
8 8.6 22.3 25.4 -3.1 4.9 6.0 4.3 2.4 1. 9 1. 9 2.0 
9 9.8 31. 8 29 .1 2.8 8.4 8.8 1. 5 0.4 1. 7 1. 7 1. 7 
10 12 .2 31. 3 29 .1 2.3 6.7 9. 1 2.2 0.8 1. 0 1. 5 1. 8 .............•..•.•................•.............................. 
Average : 10.5 30.1 28.1 1. 5 6.5 7.4 2.9 1. 6 1. 3 1. 8 2.1 
TABLE: ~ PREDICTIONS FROM FIRST DOSE 
PT KO PEAK PR PEAK ACH-PR TROUGH PR TROUGH ACH-PR 
----- ----- ------- ------ ------ --------- ------
1 46.4 39.7 6. 7 12.5 5.1 7.4 
2 21. 5 25 . 6 4.1 0.4 0.1 0.3 
3 22.9 29.3 6.4 1.1 0.9 0.2 
4 24 .4 36 .2 -11. 8 0.4 0.1 0.3 
5 29 .4 37.9 -8. 5 2.6 4.9 -2.3 
6 36 .5 25. 0 11. 5 1. 8 0.1 1. 7 
7 34.0 28.7 5.3 2.4 0.1 2.3 
8 19 .7 24.0 -4 .3 3.4 0.5 2.9 
9 40.5 29 .4 11.1 . 2.0 0.4 1. 6 
10 16.3 28.5 -12.2 0.4 0.3 0.1 
•••••••••••••••••••••••••••••••••••••••••••• 
Average: 29.2 30.4 .0.8 2.7 1. 3 1. 5 
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s tandard references ( 1) . The mean +/-SD value for clearance of 1 .8 
+/ - 0 .6 ml/k g /min a l so lies wi thin one standard dev i at ion of t he 
value of 1 . 3 +/ - 0 .6 r eported for· the general population (1 l . 
4.2.4. OVERALL PREDICTION ACCURACY. 
A t otal of 51 predicted vs achie ved peak and trough Pair s were 
s tudied and the r esults summarized in table 3 . 
.i.l 2..e..ak. Levels. 
Bi as is measured by ME = 1 .5 mg/1 with a 95% confidence interva l of 
- 2 .6 to 6.5 which includes 0. 
Precision is measured by MAE(6.5 mg/1) and RMSE(7.4 mg/1), both 
have values < 8 mg/1 
iil. Trough Levels. 
Bi as is measured by ME = 1 .3 mg/1 with 95% confidence interval of 
0 .4 to 1 .8 which does not include 0. 
Pr ecision is measured by MAE< 1 . 8 mg/ l) and RMSE (2. 1 mg/ 1), both 
have values < 4 mg /1 
4.2.5. FIRST .DQ.S£ PREDICTION ACCURACY. 
Results are summarized in table 4. 
il. £.e.ak Levels. 
Bi as is measured by ME= -1 .3 mg/1 with 95% confidence interval of 
-10.8 to 9.8 which does include 0. 
Precision is measured by MAE= 8.2 mg/1 and RMSE = 8.7 mg/1, both 
have values > 8 mg/ 1 .. 
il. Trough Levels. 
Bias is measured by ME = 1 .5 mg/1 with 95% confidence interval 0.1 
to 2.7 which does not include 0. 
Precision is measured by MAE<1.9 mg/1) and RMSEC2.9 mg/1), botr1 have 
values < 4 mg/1. 
4.2.6, ACHIEVEMENT QE THERAPEUTIC DRUG LEVELS, 
The 51 pairs of amikacin levels reflecting use of dose regimens 
determined by kinetic predictions were assessed for achievement of 
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levels with in the therapeutic r ange . 
Therapeutic Peak levels were defined as 30 + / - 10 mg/1 and toxic 










6 C 1 2%) 
Not App licable 
Five patients had all levels based on TOM predictions within the 
t herapeutic range. All 3 toxic trough levels occurred in patient 1 . 
This is partly due to an initial attempt after dose 1 to predict 
kinetic parameters from a peak level alone. The resultant excessive 
dose was implemented before kinetic parameters were re estimated 
using both peak and trough levels. The recalculated parameters 
predicted the resultant toxic level. 
Therapeutic levels were achieved in 7 patients after implementation 
of the first kinetic prediction based dose. Two Patients had to xi c 
and one patient subtherapeutic levels. 
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5..... DISCUS;ION 
A~inoglycosides are valu able antibiotics in the ma na gement of 
febrile neut rooae nic patient s with haematological disease. A 
comprehensi ve literat ure rev iew reveals that aminoglycosides r·e ta in 
a principal role wi th current ev idence not supporting t hei r 
r ep lacement with ext ended spectrum 8-lactams. It is a lso evident 
that effective and safe use of aminoglycosides requires ea r l y 
achi evement of therapeutic peak levels and the avoidance of high 
trough levels. Desp i te increasing evidence for the advantage of 
once daily am i noglycoside dosing regimens , this is not established 
for neutropaenic or other compromised patients and on the basis of 
current in vivo evidence, multip l e dose therapy is likely to remain 
necessary in this population. 
Aminoglycoside pharmacokinetics are highly variable and not . 
predictable using conventional clinical and biochemical indicators 
of patient status. It is thus not surprising that empiric and 
nomo gram based drug use frequently results in non therapeutic 
levels. In contrast, use of measured drug levels in an 
i ndividualized kinetic TOM model results in consistent achievement 
of therapeutic levels even in patients with changing renal function 
and maJor extracellular fluid shifts. 
The controversy over aminoglycoside kinetic parameter differences in 
patients with neutropaenia remains unresolved. Seriously ill 
patients appear to have increased Vd when compared to healthy 
controls. However it is important to note that the value for Vd has 
been revised upward in more recent editions of standard references 
and that values for Vd previously reported as significantly 
increased in special populations may show no difference when 
compared to revised values. It is also possible that the increased 
value for neutropaenic patients may not be significantly different 
from that for seriously ill patients without neutropaenia. This 
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s tudy fa i led to demonstrate a significant difference between t he 
estimates of Vd and CL and those reported in standard r eferences 
(1) . This fin di ng be due eitr1er to a fa i lure t o detect a di ffe r~ ence 
in kine tics or r epresent a true finding. There are two maJor 
fa ct ors l im i ting t he accuracy and value of the kinet i c estimates for 
t r, e population studied. Tt·1e Principal factor· is the small 
POPu l at i on size used. The second rel ates to study des ·i m1 and t he 
kinetic model used. This study was not designed to determine 
accurate patient kinetics but rather to assess the clinical val ue of 
t he OPT program in a specific population. The kinetic results 
reported are the average obtained for the entire period of treatment 
for each patient. For several patients this includes a significant 
pe ri od of amikacin treatment while clinically uninfected and 
apyrexial due to the Unit Protocol requirement of resolution of 
neutropaenia as a condition for cessation of antibiotic therapy, 
These kinetic parameters are thus not truly representative of the 
acutely ill neutropaenic patient. The Bayesian model kinetic 
parameter estimates for a single dose interval cannot be used to 
compensate for this bias due to the maJor influence of both 
population and individual patient prior input. This study does not 
cont r ibute to resolving the uncertainty about aminoglycoside 
kinetics in neutropaenic patients. 
This study investigated the use of a Bayesian TOM method to 
implement therapy guidelines. The study was not controlled as the 
use of TDM is well established. Overall performance of the program 
in neutropaenic Patients is reported using accepted defined 
criteria. The Peak prediction was unbiased and precise with the 
trough prediction giving biased but precise estimates. Trough 
estimate bias may be a result of the decision to use the value of 
0.4 mg/1 for entry into the OPT program when drug assays reported 
levels of less than 0.8 mg/1. Bias was not of clinical 
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si gni ficance i n maintaining trough levels bel ow 6 mg /1 . 
Initi a l predict i ons based on measurements taken after the fir s t dose 
ga ve unbi ased but imprecise Peak level and biased but precise t roug h 
leve l pred ict i ons. Trough level bias although stat is ti ca l ly 
s i gnificant, did not affect the achievement of non-to xic trough 
leve l s i n a l l patients except patient 1. The overall result was the 
achievement of 80% of peak and 94% of trougr1 levels were i n the 
t herapeutic range. 
Predictions based on first dose measurements Yielded 70% thera~eut ic 
pea k and 90% non-toxic trough levels. 
These results are acceptable and may be used to improved therapy and 
thus contributing to patient care. However model performance 
remains suboptimal and a review of the OPT model use may be of value 
in improv i ng predictive accuracy. 
Am i noglycoside kinetic variability imposes an intrinsic limit on the 
pred i ctive performance of all available programs including OPT. 
This limitation can only be minimized by a better understanding of 
the mechanisms of variability. Sampling done by a well motivated 
and trained nursing staff in an ICU does not appear to be a maJor 
source of error The current aminoglycoside assay methods used do 
not generate significant error. An area of potential improvement is 
in the initial predictive nomogram section of the OPT program. This 
is based on population data derived from standard sources at the 
time of the compilation of OPT (1986), and is unlikely to be 
representative of the population from which the subJects of this 
study are derived. Use of that baseline data for a Bayesian Program 
derived from a similar population to that of patients treated 
results in improved accuracy (58) (59). It was thus decided to 
reassess the predictive accuracy of OPT using mean values for Vd 
that are Possibly more appropriate for the patient population in 
this study, Values for Cl and the variance of Vd were not changed. 
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The values for Vd = 310 ml/ kg wa s derived from the mean value of 
the kinetic estimate for thi s study and that of 400 ml/kg as a 
r ounded off average from studies on neutropaenic patient populations 
reported in the literature (7) (22) (23) (24). Summaries of the 
results for overall and first prediction accuracy are represented in 
tables 5 and 6 respectively, 
T3ble .5...... 
Predictive Accuracy using OPT and altered Vd. 
2.£8.K LEVEL TROUGH LEVEL 
QEI w D.....3.1 w !Llill O.l:I w il.....ll w D....AQ 
ME: 1 . 5 4.2 5.8 1 . 3 0.9 0.9 
MAE: 6.5 6.5 7.3 1 . 8 1 . 8 1 . 7 
RMSE: 7.4 7.3 8.2 2. 1 2.2 2. 1 
Table 6..... 
Accuracy of predictions based on first dose levels for peak values 
using altered Vd values. 
.eEAt LEVEL 
O.l:I w .D.....31. w D....Bl1 
ME: -1 .3 2.31 4.2 
MAE: 8.2 6.8 6.8 
RMSE: 8.7 8.4 9. 1 
OPT= value achieved using unaltered OPT program 
Vd 0.31 = values achieved for substitution of Vd = 310 ml/kg for 
initial population mean of Vd. 
Vd 0.40 = values achieved for substitution of Vd = 400 ml/kg for 
initial population mean of Vd. 
All values stated are in mg/1. 
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I t is eviden t f rom this data that prediction performance was no t 
i mproved by substitution of revised values for the mean of Vd. 
Ho we ver a mo r e substantial revision of Program population data 
including the mean value for Cl and SD of Vd and Cl ma y be more 
successful. These manipulations were not performed in th i s study 
because of difficulties encountered when attempting to a l ter 
t he OPT initia l population data base file. 
70M resulted in use of a mean amikacin dose of 10.5 mg/kg whi ch is 
40% above the manufacturer's recommendation of 7.5 mg/kg/dose f or 
t wice daily use. Increased doses were administered without an 
incr eased frequency of toxic trough levels in 9 Patients even when 
ma Jor changes in renal function occurred. 
The cost effectiveness of this TOM intervention was not formally 
addressed. Previous reports have failed to prove unequivocal 
benefit due to the complexity of the analysis required. The maJor 
di fficulty is accurate measurement of the value of benefit derived 
fr om more effective treatment and decreased toxicity. The 
additional costs of use of the OPT program in this study were 
minimal and no additional infrastructure was required. The OPT 
program is available from the Department of Pharmacology, amikacin 
assays are done routinely in the Department of Microbiology and 
twice weekly aminoglycoside assay is a condition of drug use in the 
Department of Haematology treatment protocol. The Unit Pharmacist 
can easily be trained to do the kinetic predictions which take less 
than 10 minutes per patient for each entry. Thus the only 
additional cost incurred is that of the two additional drug assays 
after the first dose. On the basis of both published results and 
the findings of the survey conducted at GSH in 1990 CGroenewald P. 
et al Personal communication) it would appear that measurement of 
aminoglycoside levels without use of a predictive model to optimally 
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utilize results is not cost effective . The use of a predictive TOM 
method would thus seem rational. 
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fi...... CONCLUSION. 
A Bayesi an Computer based TOM program was introduced for the control 
of amikacin drug levels in a high risk target population. Ava i lab l e 
evidence suggests that this should improve therapeutic efficacy and 
reduce toxicity in a cost effective manner. This study failed to 
establish any significant difference in aminoglycoside kinetic 
parameters for patients with profound neutropaenia but this finding 
is of limited significance because of factors related to study 
design and the kinetic model used. OPT yielded satisfactory but 
suboptimal performance accuracy which may be improved by revision of 
the population criteria used although this was not established in 
this study. 
The OPT TDM method can be easily applied for aminoglycoside therapy 
to all ICUs at GSH and has the potential to significantly aid 
medical staff in resolving the recurrent problem of failure to 
achieve therapeutic aminoglycoside levels. Routine use of the 
method in all GSH ICUs is thus strongly recommended. 
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a.._ INDEX QE ABBR EVIATIONS, 
ABW. - actua l body weight 
ALIC. - area under curve of concentration time plot. 
8-lactam - Beta lactam antibiotic class 
Cl. - cl ear·ance 
logarithmic exponential 
ECF. - extracellular fluid 
GFR. - glomerular filtration rate 
GSH. - Groote Schuur Hospital 
ICU . - intensive care unit 
MAE. - mean absolute error 
ME. - mean error 
MIC. - minimal inhibitory concentration 
PAE.- post antibiotic effect 
PC. - personal computer 
RMSE. - root mean squared error 
SZ. - Sawchuck - Zaske 
t1/2 - half life 
TDM. - therapeutic drug monitoring 
Unit - Isolation Unit of the Department of Haematology 
Vd - volume of distribution 
£L APPENDIX. 
Individual patient result are represented in two formats. 
1) The numerical table contains the following data: 
NO - the number of administered dose. 
DATE - date of drug administration. 
DOSE total amikacin dose administered in mg. 
mg/kg - dose administered expressed in mg /kg actual body weight. 
TIME - clock time of administration. 
INT - time in hours from start of administration of previous dose of 
amikacin. 
PEAK - measured peak amikacin level in mg/1. 
P/PEAK - OPT prediction of peak level (in mg/1) based on kinetic 
parameters estimated from information available at the time 
of previous drug level assay. 
ACH-PRED - achieved minus predicted amikacin levels in mg/1. 
TROUGH - measured trough amikacin level in mg/1. 
P/TR - OPT prediction of amikacin trough level in mg/1. 
TR-PRED - achieved minus predicted trough amikacin level in mg/1. 
VD - amikacin volume of distribution estimate derived from the OPT 
program using all data at the time of estimation and expressed 
in litre. 
CL - amikacin clearance estimate derived from OPT program and 
expressed in 1/hr. 
T1/2 - amikacin half life estimate derived from the OPT program and 
expressed in hours. 
2) The graphical format displays achieved and predicted peak and 
trough levels on a common X axis which represents dose number. 
Each graph covers the period of therapy for a single patient and 
demonstrates visually the amikacin levels achieved as compared to 
those predicted. 
PATIENT 1 
NO DOSE 19/kg INT PEAK P/PEAK ACH-PRED TROUGH P/TR TR-PRED VD CL Tl/2 -- ------ ----- ----- ----- ------ -------- ------ ---- ------- ----- ---- ----
1 500 9.3 0:00 15, 1 1. 0 20.1 5.9 5.1 
2 500 9.3 11:15 
3 900 16,7 14:00 
4 900 16.7 6:00 
5 900 16,7 6:00 46.4 39.7 6.7 12.5 5,1 7.4 18,3 5.4 2.4 
6 550 10,2 6:00 
7 550 10.2 8:00 
8 550 10,2 8:00 
9 550 10,2 8:00 
10 550 10,2 7:00 19.5 26,8 -7.3 3.8 3.4 0.4 20, 1 6.1 2,3 
11 550 10,2 9:00 
12 650 12.1 8:00 
13 650 12,1 8:00 
14 650 12.1 8:00 21.4 28.4 -7.0 4.4 3.4 1.0 22.0 6.2 2,5 
15 650 12.1 8:00 
16 650 12.1 8:00 
17 650 12,1 8:00 
18 650 12.1 8:00 
19 650 12.1 8:00 
20 650 12.1 8:00 
21 650 12.1 8:00 
22 650 12.1 8:00 
23 650 12.1 8:00 34.9 22,0 12,9 13.3 4.4 8.9 23,4 3.0 5.3 
24 550 10,2 18:00 24,3 23.6 0.7 9.4 2,6 6.8 36,1 2.7 9,1 
.. --=--- -==-- =---- -==-· -----= -------- ----== ---- ------- ----- ---- -=--




























































































































































































NO DATE DOSE 19/ kg TINE INT PEAK P/PEAk ACH-PRED TROU6H P/TR TR-PRED YD CL Tl /2 
-- -------- ------ ----- ----- ----- ----- ------ -------- ------ ---- ------- ------ ------ ----
I 13/06/90 750 13,8 10:50 0:00 20.3 16,510 12,795 0.9 
2 13/06/90 750 13,8 22:00 11:10 
3 14/06/90 750 13.8 5:00 7:00 21. 5 25.6 -4, I 0.4 0.1 0.3 18.749 13,008 I. 0 
5 14/06/90 850 15.7 22:00 8:00 
6 15/06/90- 850 15.7 6:00 8:00 
7 15/06/90 850 15.7 14:00 8:00 28.S 27.2 1. 3 0.4 0.2 0,2 18.738 12.076 1.1 
8 15/06/90 850 15.7 22:00 8:00 
9 16/06/90 8SO 15.7 6:00 8:00 
10 16/06/90 8SO 15. 7 14: 00 8: 00 
II 16/06/90 8SO 15.7 22:00 8:00 
12 17/06/90 850 15.7 6:00 8:00 
13 17 /06/90 850 15.7 14:00 8:00 
14 17/06/90 850 15.7 22:00 8:00 
IS 18/06/90 850 15.7 6:00 8:00 
16 18/06/90 850 15,7 14100 8:00 38.4 28.3 10.1 1,2 0.3 0.9 15.963 9.722 1.1 
17 18/06/90 500 9.2 22:30 8:30 
18 19/06/90 500 9.2 6:30 8100 
19 19/06/90 500 9.2 14:30 8:00 21.0 20,1 0.9 0.4 0.3 0.1 15,558 8,964 I. 2 
20 19/06/90 600 11. 1 22: 30 8: 00 
21 20/06/90 600 11.1 6:30 8:00 
22 20/06/90 600 II. I 14:00 8:00 
23 20/06/90 600 11.1 22:30 8:00 
24 21/06/90 600 11.1 6:30 8:00 31.3 25.4 5.9 2.0 0.4 1.6 15.477 6.010 I. 8 
25 21/06/90 600 II, I 14:30 8:00 
26 21/06/90 600 11,1 22:30 8:00 
27 22/06/90 600 11.1 6:30 8100 
28 22/06/90 600 II. I 14: 30 8:00 
29 22/06/90 600 II, I 22: 30 8: 00 
30 23/06/90 600 11.1 6:30 8:00 
31 23/06/90 600 11.1 14130 8:00 
32 23/06/90 600 11, I 22:30 8:00 
33 24/06/90 600 11.l 6:30 8:00 
34 24/06/90 600 11,1 14130 8:00 
35 24/06/90 600 11,1 22:30 8100 
36 25/06/90 600 11.1 6:30 8100 39.1 30.4 8.7 2,1 2.0 0.1 13.983 5.533 l, 8 
37 25/06/90 500 9.2 14:30 8:00 
38 25/06/90 500 9.2 22:30 8:00 
39 26/06/90 500 9.2 6:30 8100 
40 26/06/90 500 9.2 14130 8100 
41 26/06/90 500 9.2 22:30 8:00 
42 27/06/90 500 9.2 6130 8:00 
43 27/06/90 500 9.2 14130 0100 
44 27/06/90 500 9.2 22:30 8:00 
45 28/06/90 500 9.2 6:30 8:00 29.6 27.8 1.8 5.2 I, 7 3.5 15.413 3.957 2.7 
46 28/06/90 500 9.2 14:30 8:00 
47 28/06/90 500 9.2 22:30 8:00 
48 29/06/90 500 9.2 6130 8100 
49 29/06/90 450 8.3 14:30 8:00 
so 29/06/90 450 8.3 22:30 8:00 
SI 30/06/90 450 8.3 6:30 8:00 
52 30/06/90 450 8.3 14:30 8:00 
53 30/06/90 450 8.3 22:30 0100 
54 01/07/90 450 8.3 6:30 8:00 
55 01/07/90 450 8.3 14130 8:00 
56 01/07/90 450 8.3 22:30 8:00 
57 02/07/90 450 8.3 6:30 8100 24.6 27.6 -3.0 3.9 4.6 -0.7 15.614 4.400 2.5 
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NO DATE DOSE 1g/kg TIME INT PEAK P/PEAK ACH-PRED TROUGH P/TR TR-PRED YO CL Tl/2 
-- -------- ------- ----- ----- ----- ----- ------ -------- ------ ---- ------- ------ ----- ----
1 'ZfJ/06/90 1000 17.8 18:40 0:00 48.4 13,735 4.400 2.2 
2 21/06/90 500 8.9 8:00 13:20 22.9 29.3 -6.4 I. I 0.9 0.2 1S.366 4.803 2.2 
3 21/06/90 soo 8.9 20:00 12:00 
4 22/06/90 soo 8.9 8:00 12:00 
S 22/06/90 soo 8.9 20:00 12:00 
6 23/06/90 soo 8.9 8:00 12:00 
7 23/06/90 soo 8.9 20:00 12:00 
8 24/06/90 500 8.9 8:00 12:00 
9 24/06/90 500 8.9 20:00 12:00 
10 25/06/90 soo 8.9 8:00 12:00 19.7 26.4 -6.7 0.4 0.0 -0.4 16.314 S.700 2.0 
11 25/06/90 600 10.7 20:00 12:00 
12 26/06/90 600 10.7 8:00 12:00 
13 26/06/90 600 10.7 20:00 12:00 
14 26/06/90 600 10.7 8:00 12:00 
IS 27/06/90 600 10.7 22:00 12:00 
16 28/06/90 600 10.7 6130 10:30 32.3 28.8 3.5 2,3 0.6 1,714,110 4.63S 2.1 
17 28/06/90 600 10.7 20:00 13:30 
18 29/06/90 600 10.7 8:00 12:00 
19 29/06/90 600 10.7 20:00 12:00 
20 30/06/90 600 10.7 8:00 12:00 
21 30/06/90 600 10.7 20:00 12:00 
22 01/06/90 · 600 10.7 8:00 12:00 
23 01/06/90 600 10.7 20:00 12:00 
24 02/06/90 600 10,7 8:00 12:00 34.9 33.9 1,0 1,7 0.9 0.8 14.135 3.930 2,S 
25 02/06/90 S50 9.8 20:00 12:00 
26 03/06/90 500 8.9 8:00 12:00 
27 03/07/90 500 8.9 20:00 12:00 
28 04/07/90 500 8,9 8:00 12:00 
29 04/07/90 500 8.9 20:00 12:00 
30 05/07/90 500 8.9 8:00 12:00 32,0 29.8 2,2 1,4 1,4 o.o 13,463 3.803 2,S 
31 05/07/90 450 8.0 20100 12:00 
32 06/07/90 450 8.0 8:00 12:00 
. 33 06/07/90 450 8,0 22:00 12:00 
34 07/07/90 450 8,0 8:00 12:00 
35 07/07/90 450 8.0 20:00 12:00 
36 08/07/90 450 8.0 8:00 12:00 
37 08/07/90 450 8.0 20:00 12:00 
38 09/07/90 450 8,0 8:00 12:00 21, 8 28,0 -6.2 0.4 1,3 -0.9 14,314 5,651 1,8 
39 09/07/90 450 8,0 20:00 12:00 
40 10/07/90 450 8.0 8:00 12:00 
41 10/07/90 450 0.0 20:00 12:00 
42 11/07 /90 450 8.0 8:00 12:00 
43 11/07/90 450 0.0 20:00 12:00 
44 12/07/90 450 0.0 0:00 12:00 18.4 23,6 -5.2 1,6 0.3 1,3 18.982 4.501 2,9 
45 12/07/90 500 8.9 20:00 12:00 
46 13/07/90 500 8.9 8:00 12:00 
47 13/07/90 500 8.9 20:00 12:00 
48 14/07/90 soo 8.9 8:00 12:00 
49 14/07 /90 500 8.9 20:00 12:00 
so 15/07/90 500 8.9 8:00 12:00 
SI 15/07/90 soo 8.9 20:00 12:00 
52 16/07/90 500 8,9 8:00 12:00 25,S 21,1 4,4 I, 2 I, 6 -0.4 16.39S 4,548 2,5 
53 16/07/90 500 8.9 20:00 12:00 
54 17/07/90 500 8.9 8:00 12:00 
55 17/07/90 500 8.9 20:00 12:00 
56 18/07/90 500 8.9 8:00 12:00 
57 18/07/90 500 8.9 20:00 12:00 
58 19/07/90 500 8.9 8:00 12:00 26,3 25.7 0.6 1,6 1.2 0.4 16.031 4.230 2,7 
59 19/07/90 500 8.9 20:00 12:00 
60 20/07/90 500 8.9 8:00 12:00 
:a :zzaa::: :s:sa:s =••=• :s::s :sa:s ===== :a:a:: =••••==•=•••=•::as :s:a:aa :s:z:: ::::: :::: 
























































































































































































NO DATE DOSE 11g/kg TIME INT PEAK P/PEAK ACH-PRED TROUGH P/TR TR-PRED VD CL T!/2 -- -------- ------ ----- ----- ----- ----- ------ -------- ------ ---- ------- ------ ----- ----
r 251061110 750 14.1 10: 10 0:00 30.4 13.785 7.S81 I. 3 
2 2S/06/90 7SO 14.1 20:00 9:50 
3 26/06/90 7SO 14.1 8:00 12:00 
4 26/06/90 750 14.1 22:00 12:00 
5 27/06/90 750 14.1 8:00 12:00 
6 27/06/90 750 14.1 20:00 12:00 
7 28/06/90 750 14.1 6:30 10:30 24.4 36.2 -11. 8 0.4 0.1 0.3 18.128 7.897 I. 6 
8 28/06/90 7SO 14.1 20:00 13:30 
9 29/06/90 750 14.1 8:00 12:00 
10 29/06/90 750 14.1 20:00 12:00 
11 30/06/90 750 14.1 8:00 12:00 
12 30/06/90 750 14.1 20:00 12:00 , 
13 01/07/90 750 14.1 8:00 12:00 
14 01/07/90 750 14,1 20:00 12:00 
15 02/07/90 750 14.1 8:00 12:00 35.7 30.1 5.6 0.4 0.2 0.2 15.088 6.044 I. 7 
16 02/07/90 750 14,1 20:00 12:00 
17 03/07/90 750 14.1 6:30 10:30 35.5 37,2 -1. 7 I. 2 0.5 0.7 15.019 5.808 1.8 
18 03/07/90 600 11.3 20:00 13:30 
19 04/07/90 600 11.3 8:00 12:00 
20 04/07/90 600 11,3 20:00 12:00 
21 05/07/90 600 11.3 8:00 12:00 I. 4 0.4 I. 0 
22 05/07/90 550 10.3 20:00 12:00 
23 06/07/90 550 10.3 8:00 12:00 29.5 30.2 -0.7 0.9 0.4 0.5 14,859 4.734 2.2 
24 06/07/90 550 10.3 20:00 12:00 
25 07/07/90 550 10.3 8:00 12:00 
26 07/07/90 550 10.3 20:00 12:00 
27 08/07/90 550 10.3 8:00 12:00 
28 08/07/90 550 10.3 20:00 12:00 
29 09/07/90 550 10.3 8:00 12:00 32.6 29.8 2.8 2.8 0.9 1.9 14.552 4.077 2.5 
30 09/07/90 500 9.4 20:00 12:00 
31 10/07/90 500 9.4 8:00 12:00 
32 10/07/90 500 9.4 20:00 12:00 
33 11/07 /90 500 9.4 8:00 12:00 
34 11/07/90 500 9.4 20:00 12:00 
35 12/07/90 500 9.4 8:00 12:00 30.5 28.9 I. 6 I. 2 1, 3 -0.1 13.881 4.018 2.4 
36 12/07/90 500 9.4 20:00 12:00 
37 13/07/90 500 9.4 8:00 12:00 
38 13/07/90 500 9. 4 20: 00 12: 00 
39 14/07/90 500 9.4 8:00 12:00 
40 14/07 /90 500 9.4 20:00 12:00 
41 15/07/90 500 9.4 8:00 12:00 
42 15/07/90 500 9.4 20:00 12:00 
43 16/07/90 500 9.4 8:00 12:00 23. 9 · 29. 9 -6.0 I. 2 1.2 o.o 16,211 4.538 2.5 
44 16/07 /90 500 9.4 20:00 12:00 
45 17/07/90 500 9.4 8:00 12:00 
== ======== ====== ::x:: :2::: ===== ===== ====== ======== ====== ==== ======= ====== ===== ==== 
































































































































































































NO DATE DOSE mg/kg TIME INT PEAK P/PEAK ACH-PRED TROUGH P/TR TR-PRED VD CL Tl/2 
\ 27/0b/90 750 12.2 12:30 0:00 39.3 12.91S 3.778 3.9 
Z 'lT/Oh/90 sso 8.9 22:30 10:00 
3 28/06/90 sso 8.9 6:30 8:00 
4 28/06/90 5SO 8.9 14:30 8:00 29.4 37.9 -e.s 2.6 4.9 -2.3 14.121 s.020 2.0 
S 28/06/90 sso 8.9 22:30 8:00 
6 29/06/90 sso 8.9 6:30 8:00 
7 29/06/90 sso 8.9 14:30 8:00 
8 29/06/90 sso 8.9 22:30 8:00 
9 30/06/90 sso 8.9 6:30 8:00 
10 30/06/90 sso 8.9 14:30 8:00 
11 30/06/90 sso 8.9 22:30 8:00 
12 01/07/90 sso 8.9 6:30 8:00 
13 01/07/90 sso 8.9 14:30 8:00 
14 01/07/90 sso 8.9 22:30 8:00 
1S 02/07/90 sso 8.9 6:30 8:00 26.9 31. 7 -4.8 3.1 2.6 O.S 1S.414 5.088 2.1 
16 02/07/90 sso 8.9 14:30 8:00 
17 02/07/90 550 8.9 22:30 8:00 
== ======== ====== ===== ===== ===== ===== ====== ======== ====== ==== ======= ====== ===== ==== 
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NO DATE DOSE mg/kg TINE INT PEAK P/PEAK ACH-PRED TROUGH P/TR TR-PRED VD CL Tl/2 -- -------- ------ ----- ----- ---- ----- ------ -------- ------ ---- ------- ------ ------ ----
1 
02/07/90 7SO 13.1 23:30 0:00 32.6 11. 5S5 10. 029 0.8 
Z 03/07/90 500 8.7 8:00 8:30 
3 03/07/90 550 9.6 16:30 8:30 
4 03/07/90 5SO 9.6 22:30 8:00 
5 04/07/90 550 9.6 6:30 8:00 
6 04/07/90 550 9.6 14:30 8:00 
7 04/07/90 550 9.6 22:30 8:00 
8 05/07/90 550 9.6 6:30 8:00 36.5 25.0 11. 5 I. 8 0.1 1.7 18.734 7.904 I. 6 
9 05/07/90 550 9.6 14:30 8:00 
10 05/07/90 500 8.7 22:30 8:00 
11 06/07/90 500 8.7 6:30 8:00 27.5 20.2 7.3 4.9 I. 1 3.8 18.297 6.736 I. 9 
12 06/07/90 500 8.7 14:30 8:00 
13 06/07/90 500 8.7 22:30 8:00 
14 07/07/90 500 8.7 6:30 8:00 
15 07/07/90 500 8.7 14:30 8:00 
16 07/07/90 500 8.7 22:30 8:00 
17 08/07/90 500 8.7 6:30 8:00 
18 08/07/90 500 8.7 14:30 8:00 
19 08/07/90 500 8.7 22:30 8:00 
20 09/07/90 500 8.7 6:30 8:00 27.7 21. 9 5.8 0.4 I. 7 -1.3 12.260 6.889 1. 2 
21 09/07/90 500 8.7 14:30 8:00 
22 09/07/90 500 8.7 22:30 8:00 
23 10/07/90 500 8.7 6:30 8:00 
24 10/07/90 500 8.7 14:30 8:00 
25 10/07/90 500 8.7 22:30 8:00 
== ======== ====== ===== ===== ==== ===== ====== ======== ====== ==== ======= ====== ====== ==== 
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NO DATE DOSE 11g/kg TINE INT PEAK P/PEAK ACH-PRED TROUGH P/TR TR-PRED VO CL Tl /2 -- -------- ------ ----- ----- ----- ----- ------ -------- ------ ---- ------- ------ ------ ----
1 03/07/90 750 13.0 18:30 0:00 22.1 14.991 12.588 0.8 
2 0•107/90 500 13.0 8:00 13:30 
3 04/07/90 800 13.0 14:30 6:30 
4 04/07/90 800 13.0 22:30 8:00 
5 05/07/90 800 13.9 6:30 8:00 34.0 28.7 5.3 2.4 0.1 2.3 22.591 10.100 I. 6 
6 05/07/90 800 13.9 14:30 8:00 
7 05/07/90 750 13.0 22:30 8:00 
8 06/07/90 750 13.0 6:30 8:00 
9 06/07/90 750 13.0 14:30 8:00 36.3 24.5 11. 8 3.7 1.1 2,6 23.475 8.315 2.0 
10 06/07/90 700 12.2 22:30 8:00 
11 07/07/90 700 12.2 6:30 8:00 
12 07/07/90 700 12.2 14:30 8:00 
13 07/07/90 700 12.2 22:30 8:00 
14 08/07/90 700 12.2 6:30 8:00 
15 08/07/90 700 12.2 14:30 8:00 
16 08/07/90 700 12,2 22:30 8:00 
17 09/07/90 700 12.2 6:30 8:00 35.9 24.3 11. 6 3.3 2.0 1.3 18.080 6.362 2.0 
18 09/07/90 700 12.2 14:30 8:00 
19 09/07/90 600 10.4 22:30 8:00 
20 10/07/90 600 10.4 6:30 8:00 
21 10/07/90 600 10.4 14:30 8:00 
22 10/07/90 600 10.4 22:00 8:00 
23 11/07/90 600 10.4 6:30 8:00 
24 11/07/90 600 10.4 14:30 8:00 
25 11/07/90 600 10.4 22:30 8:00 
26 12/07/90 600 10.4 6:30 8:00 40.0 27.1 12.9 1. 9 2.3 -0.4 14.983 5. 972 1. 7 
27 12/07/90 500 8.7 14:30 8:00 
28 12/07/90 500 8.7 22:30 8:00 
29 13/07/90 500 8.7 6:30 8:00 
:: ======== ====== ====• =••== ====• ===== ====== ======== ====== ==== ======= ====== ====== ==== 
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NO DATE DOSE 1g/kg TIME INT PEAK P/PEAK ACH-PRED TROUGH P/TR TR-PRED VD CL Tl/2 -- -------- ------ ----- ----- ----- ----- ------ -------- ------ ---- ------- ------ ----- ----
I 22/07 /90 500 8.6 19:20 0:00 19.6 16.228 5.719 2.0 
2 23/07/90 500 8.6 8:00 12:40 19.7 24.0 -4.3 3.4 0.5 2.9 21.958 3.530 4.3 
3 '23/07/90 500 8.6 20:00 12:00 
4 24/07/90 500 8.6 8:00 12:00 
5 24/07/90 500 8.6 20:00 12:00 
6 25/07/90 500 8.6 8:00 12:00 
7 25/07/90 500 8.6 20:00 12:00 
0 26101190 500 8.6 8:00 12:00 25.4 23.6 1.8 6.0 4.0 2.0 19.612 2.928 4.6 
9 27/07/90 500 8.6 2:00 18:00 
10 27/07/90 500 8.6 20:00 18:00 
11 28/07/90 500 8, 6 14': 00 18: 00 
12 29/07/90 500 8.6 14:00 18:00 
13 30/07/90 500 8.6 2:00 18:00 
14 30/07/90 500 8.6 8:00 6:00 
15 01/08/90 500 8.6 0:00 40 
16 01/08/90 500 8.6 18:00 18:00 
17 02/08/90 500 8.6 12:00 18:00 25.6 24.5 1.1 3.4 1. 9 1.5 17.094 2,206 5.4 
18 03/08/90 500 8.6 6:00 18:00 
19 05/08/90 500 8.6 0:00 18:00 
20 05/08/90 500 8.6 18:00 18:00 
21 06/08/90 500 8.6 12:00 18:00 18.3 29.4 -11.1 4.4 3.3 I.I 23.280 2.859 1. 5 
22 07/08/90 500 8.6 8:00 18:00 
== ======== ====== ===== ===== ===== ===== ====== ======== ====== ==== ======= ====== ===== ==== 
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NO DATE DOSE mg/kg TI~E INT PEAK P/PEAK ACH-PRED TROUGH P/TR TR-PRED VD CL Tl/2 
1 30/07/90 500 9.4 17:30 0:00 19.3 
2 30/07/90 500 9,4 22:00 2:30 
! 31/07/90 500 9.4 8:00 12:00 24.3 0.4 15.249 b.129 !. 7 
4 31/07/90 500 9.4 20:00 12:00 
5 01/08/90 bOO 11.3 8:00 12:00 
6 01/08/90 bOO 11.3 20:00 12:00 
7 02/08/90 600 11.3 8:00 12:00 40.5 29.4 11. 1 2.0 0.4 1.6 13.12S S,147 1. 8 
8 02/08/90 soo 9.4 20:00 12:00 
9 03/08/90 500 9.4 8:00 12:00 23. 1 28.7 -S.6 2. 1 0.4 1.7 14.102 5.174 I. 9 
10 03/08/90 500 9.4 20:00 12:00 
11 04/08/90 soo 9.4 8:00 12:00 
12 04/08/90 soo 9.4 20:00 12:00 
13 OS/08/90 soo 9.4 8:00 12:00 
== ======== ====== ===== ===== ===== ===== ====== ======== ====== ==== ======= ====== ===== ==== 































































































































































































NO DATE DOSE ag/kg TINE INT PEAK P/PEAK ACH-PRED TROUGH P/TR TR-PRED VD CL T!/2 -- -------- ------- ----- ----- ----- ----- ------ -------- ------ ---- ------- ------ ------ ----
1 01/08/90 7SO 11.1 11: 4S O: 00 21.1 20.828 8,549 1. 7 
2 01/08/90 800 11.8 20:00 10: IS 
3 02/08/90 800 11.8 8:00 12:00 16.3 28.S -12.2 0.4 0.3 0. 1 27. 38S 1 O, 091 1. 9 
4 02/08/90 1000 14.8 20:00 12:00 
S 03/08/90 1000 14,8 8:00 12:00 40.2 28. 1 12.1 1. s o.s 1. 0 24. 739 8.840 0.5 
6 03/08/90 900 13.3 20:00 12:00 
7 04/08/90 900 13.3 8:00 12:00 
8 04/08/90 900 13.3 20:00 12:00 
9 OS/08/90 900 13.3 8:00 12:00 
10 OS/08/90 900 13.3 20:00 12:00 
11 06/08/90 900 13,3 8:00 12:00 44.8 28,3 16.5 3.0 0.6 2.4 19,423 6,749 2.0 12 06/08/90 700 10.4 20:00 12:00 
13 07/08/90 700 10.4 8:00 12:00 28.7 28,2 0.5 3.7 0.6 3.1 22,173 4,317 3,6 
14 07/08/90 700 10,4 20:00 12:00 
IS 08/08/90 700 10.4 8:00 12:00 
16 08/08/90 700 10.4 20:00 12:00 
17 09/08/90 700 10.4 8:00 12:00 31. 7 29.3 2,4 2,2 0.8 1. 4 19,903 4.810 2.9 18 09/08/90 700 10.4 20:00 12:00 
19 10/08/90 700 10.4 8:00 12:00 
20 10/08/90 700 10.4 20:00 12:00 
21 11/08/90 700 10.4 8:00 12:00 
22 11/08/90 700 10,4 20:00 12:00 
23 12/08/90 700 10.4 8:00 12:00 
24 12/08/90 700 10.4 20:00 12:00 
2S 13/08/90 700 10.4 8:00 12:00 
26 13/08/90 700 10.4 20:00 12:00 
27 14/08/90 700 10.4 8:00 12:00 31.0 31.1 -0.1 0.4 2,2 -1. 8 17,550 6.871 1. B 28 14/08/90 700 10.4 20:00 12:00 
29 15/08/90 700 10,4 8:00 12:00 
30 lS/08/90 700 10.4 20:00 12:00 
31 16/08/90 700 10.4 8:00 12:00 26,B 30,1 -3.3 1. 2 0,4 0.8 19.113 6. 776 2.0 32 16/08/90 700 10.4 20:00 12:00 
33 17/08/90 700 10.4 8:00 12:00 
:z ======== ======• ::::2 ===== =••== ===== ====== ======== ====== ==== ======= ====== ====== ==== Average: 762 11,3 30.1 29.1 2.3 1.8 0.8 1. O 21. 389 7, 12S 2.1 
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